ML14247A523

Attachment 5, PBAPS Calculation PM-1168, Post-CRDA Release from RCS Sample Line, Revision 0

ML14247A523
Person / Time
Site:	Peach Bottom
Issue date:	09/03/2014
From:	Gita Patel Exelon Generation Co
To:	Office of Nuclear Reactor Regulation
References
CC-AA-309-1001, Rev 8, PM-1168, Rev 0
Download: ML14247A523 (68)

Text

Attachment 5 Peach Bottom Atomic Power Station, Units 2 and 3 NRC Docket Nos. 50-277 and 50-278 Revise Technical Specifications to Eliminate Main Steam Line Radiation Monitor Trip Function PBAPS Calculation PM-1168, "Post-CRDA Release From RCS Sample Line," Revision O

CC-AA-309-1001 Revision 8 ATTACHMENT 1 Desi20 Analysis Cover Sheet Design Analysis I Last Page No. ' 67 Analysis No.: 1 PM-1168 Revision: 1 0 Major 181 MlnerO

Title:

3 Post-CRDA Release From RCS Sample Line EC/ECR No.: 4 13-004'14 - Revision:' 0 Station(s): 1 Peach Bottom Componcnl(s):"

Unit No.: 1 2aad3 N/A Discipline: 9 PEDM Descrip. Code/Keyword: 11 EPU;AST Safety/QA Cl$s: u SR System Code: u 912 Structure: u N/A CONTROLLED DOCUMENT .REFERENCES ""

Document No.: From/To Document No.: From/To PM-1057 From M-00300 From PEAM-EPU-6.1 From M-388 From PM-10SS From CB-407 From 6280-M-884 From VFSAR io.btcs ti.9 .to 4 1+.i.:J. -ro Is this Design Analysis Safeguards Information? 16 YesO ...,..No~ H ya, tee SY-AA-101-106 Uya, Does this Design Analysis concain Unverified Assumptions? 11 YesO NoE8l ATl/AR#:

Th,is Design Analysis SUPERCEDES: 11 NIA in its entirety.

Descripdoo of Revtlloa (list cbH&ed pqes w~ea all ..P,S of orf&lul aulysJla. were aot dwlpd): '"

This calculation analyzes the radiologiciU consequences of post-CRDA release from the reactor waler (RW) sample line and occupational dose rate in the sampling area.

Preparer: zo Method of Review: 11 Gopal J. Patel (NUCORE) .

Print Name DetU1oc1R.mw181 -~.L_

S~N~ 07114/2014 Date TestingO Reviewer: u Mark L Drucker (NUCORE) . ~: 07/1412814 Print Name S Name . Date Review Notes: 13 Independent review ~ Peer rcriew 0 (For Esttrul Aaalyta Only)

External Approver: :w Print Name Sign Name Date Exelon Reviewer: 25 Print Name Stan Name Date Independent 3n1 Party Review Reqd? u Yes 181 No 0 \'Tf>~ B'f * .'\m'f .-. 1.<be'I" ~ f..~ ,(11D/1"\

Exelon Approver: 27 ~e.$ Ch, *z.evu  ;/;, rO, :Z-- 7 /11/ I'/

Print Name Sll!i Nibbe II Date v v v

CALCULATION NO. PM-1168 REV.No. 0 PAGE NO. 2 of 67 REVISION HISTORY Revision Description 0 Initial issue

CALCULATION NO. PM-1168 REV. No. 0 SHEET REVISION INDEX SHEET REV SHEET REV

_, I 0 2 ()

3 ()

4 0 Attachment 13.1 0 5 0 Attachment 13.2 0 6 () Attachment I 3.3 0 7 0 Attachment 13.4 0 8 0 Attachment 13.5 0 9 ()

10 0 11 0 12 0 13 0 14 0 15 0 16 0 17 0 18 0 19 0 20 0 21 ()

22 0 23 0 24 0 25 0

c CALCULATION NO. PM-1168 REV.No. 0 **c-* PAGE NO. 4 of 67 TABLE OF CONTENTS Section Sheet No.

Cover Sheet Revision History 2 Page Revision Index 3 Table of Contents 4 LO Purpose 5 2.0 Methodology 5 3.0 Acceptance Criteria 7 4.0 Assumptions 8 5.0 Design Inputs 9 6.0 Computer Codes & Regulatory Compliance 13 7.0 Calculations 14 8.0 Results Summary & Conclusions 16 9.0 References 17 10.0 Tables 19 11.0 Figures 23 12.0 Affected Documents 25 13.0 Attachments 25

13. l RADTRAD Output File: PCRDASMPOO.oO 26 13.2 MicroShield Output File: PBRWSAMP.MS5 40 13.3 RADTRAD Nuclide Inventory File: PBCRDASMPOO_def.txt 43 t3.4 RADTRAD Release Fraction and Timing File: pbcrda_rfUxt 53 13.5 RADTRAD Dose Conversion Factor File: pbcrda_fgl 1&12.txt 54 1st Pass Attributes - General Overview 65 2 51 Pass Attributes - Technical Review 66 3rd Pass Attributes - Administrative 67

REV. No. 0 1.0 PURPOSE The purpose of this calculation is to determine the Exclusion Area Boundary (EAB), Low Population Zone (LPZ), and Control Room (CR) doses due to the Post-Control Rod Drop Accident (CRDA) release from the Reactor Coolant System (RCS) sampl.e line. This calculation uses the Alternative Source Term (AST) methodology, the TEDE dose criteria of l 0 CFR 50.67, guidance in RO 1.183, Appendix C and NED0-3 l400A, and the Extended Power Uprate (EPU) core inventory. This calculation assumes that the main steam line radiation monitors (MSLRM) no longer provide a signal for automatic closure of the main steam line drain valves and main steam and reactor water sample line valves, which establishes an unprocessed release to the environment.

2.0 METHODOLOGY 2.1 Post-CRDA Release Path Elimination of the MSLRM system high radiation trip functions for initiating automatic closure of the Main Steam line drain valves and Main Stearn and Reactor Water (RW) sample line valves were not evaluated in NED0-3 l400A (Ref. 9.6). The flow from the Main Steam line drain valves ultimately travels to the main condenser just as the flow from the main steam isolation valves (MSIVs). Therefore, any radioactive material passing through the Main Steam line drain valves to the main condenser and through the Offgas Treatment system is treated identically to any radioactive material that would pass through the MSIVs and the resulting dose consequences would be the same as those in Reference 9.12, Section 8.1.

With respect to deleting the MSLRM high radiation trip function to close the Main Steam and Reactor Water sample line valves on a MSLRM system high radiation signal, the following bounding reactor water sampling scenario is postulated based on the PBAPS Chemistry Procedure for Sampling of Reactor Water (Reference 9.10). As discussed Section 2.4, the post-CRDA dose rate from the RW sample will instantly exceed the radiation zone allowable dose rate limit and the area radiation monitor located in the sample room will alarm to alert the chemist to evacuate the area. Also, the occurrence of a CRDA activates the emergency level, which further alerts the non-essential plant personnel to evacuate protected area immediately a safe manner (Ref. 9.19, Sections 3.0 & 4.0). No credit is taken for the chemist securing the sampling process. Instead, it is assumed that the purging of the RW sample continues for 60 minutes until the sample valves are closed by a Control Room operator. This assumption COMb1vicd \'<.hth a noN11if\a\ f'lowro..tc.. 1 pru111de.. o. c.on.scn1o:nve..-hite..1 n:.1eo.sc:.

• Sample purge rate= 500 ml/min = 500 cc/min (Ref. 9.10, Section 8.5.6)

Total RW released during l hr purging before the sample valves are closed

= 60 minutes x 500 cc/min =30,000 cc Total RW release during sampling

= 30,000 cc x (1000 cc/Iiterr 1 x (3.785 Iiter/gallon) 1 x (7.481 gallon/ft\ 1 = 1.06 ft 3 Therefore, a maximum volume of 1.06 ft 3 of reactor water is expected to released during the sampling process. The post CRDA activity listed in Table 3 is postulated to directly released to the environment via the reactor building vent stack (Ref. 15) without being filtered by any charcoal filter.

2.2 CRDA Source Term The post-CRDA reactor coolant (RC) isotopic activity is Tables l & 2 using the input information from Reference 9.12 including the uprated core inventory, peaking factor, number of

CALCULATION NO. PM-1168 REV. No. 0 fuel rods damaged during the CRDA, fission product release fractions from the damaged and melted fuel, and gap release fractions.

Consistent with RG 1.183 (Ref. 9.1, Appendix C, Sections 3.3 and 3.4), the CRDA gap activity transport from the damaged fuel through the turbine and to the condense consists of iodine, noble gases, and alkali metals (cesium and rubidium).

The post-CRDA RC activity is distributed over the total RC volume to calculate the RC activity concentration (Ci/ft3 ) in Table 3, which is multiplied by the released reactor water (RW) volume of 0.265 ft3 (Section 2.1) to calculate the post-CRDA isotopic activity in the RW sample (Table 3).

Since the temperature of the RW liquid exceeds 2 l 2°F, the fraction of iodine and alkali metals in the RW liquid that become airborne is assumed equal to the fraction of the leakage that flashes to vapor. All of the noble gas in the RW liquid is assumed to become airborne.

The RADTRAD Nuclide Inventory File (N1F) PBCRDASMP_def.txt (Table 3) is created to be used with the post-CRDA RW sample release.

2.3 RADTRAD Release Models This analysis uses Version 3.03 of the RADTRAD computer code to calculate the post-CRDA radiological consequences from the RW sample release. The RADTRAD code was developed by Sandia National Laboratories, the NRC's technical contractor, for the staff to use in establishing fission product transport and removal models and in estimating radiological doses at selected receptors at nuclear power plants. The RADTRAD3.03 code is documented in NUREG/CR-6604 (Ref. 9.2) and maintained as Exelon Software ID Number EX0004754 (Ref. 9.11).

The post-CRDA activity from the RW sample is postulated to directly release to the environment at the ground level release as shown in Figure l from the reactor building vent stack (Reference 9 .15). The XIQs for these release paths are listed in Design Input sections 5.3.3.7 (CR) and 5.3.4 (offsite locations).

The Control Room Emergency Ventilation (CREV) system is not credited in the analysis. The CR is assumed to operate in a normal mode of operation with a maximum HV AC inflow rate of 20,600 cfm (Design Input section 5.3.3.2) plus an additional unfiltered inieakagc of 500 cfm for the entire duration of the accident. The resulting doses at the EAB, LPZ, and CR locations are compared with the dose acceptance criteria in Section 8.0.

The RADTRAD V3.03 (References 9.2 & 9.11) nuclide inventory file (NIF) PBCRDASMP_def.txt is developed using the post-CRDA activity in curies released to the environment from the RW sample (Table 3); therefore, the thermal power level is set to unity in the RADTRAD input. The release fraction and timing (pbcrda_rft.txt) is used to postulate an instantaneous post-CRDA release. The RADTRAD V3.03 dose conversion factor (DCF) File (pbcrda_fgl 1&12.txt) is based on DCFs obtained from References 9.7 & 9.8. The NIF and DCF files are modified to include additional significant radionuclides. The EAB, LPZ, and CR doses from RADTRAD output file PCRDASMPOO.oO are listed Section 8. l.

2.4 Post~CRDA Sample Line Dose Rate The of the sample line is bounded by a stainless steel Schedule 80S 314" diameter pipe per M-326 sheets 2 and lO (Ref. 9.24). The piping data for 3/4" Schedule 80S for RW sample line is obtained from Reference 9.14 (see Design Input 5.3.2.6). MicroShield model is developed for a dose receptor 1 foot away from the midpoint a 20 feet long RW sample line having the nominal inside diameter of

0. 742" with nominal wall thickness of 0.154" and nominal outside diameter 1.05". Due to

CALCULATION NO. PM- 1168 REV. No. 0 self-shielding and distance, the dose contribution is negligible from the ends of the small diameter RW sample line (i.e., at or further away than 10 feet).

The post-CRDA isotopic activities in the RW sample line are determined in Table 4 using the RW sample line volume and the post-CRDA contact dose rate was determined at one foot from the surface of the RW sample line to be 27.250 rem/hr (MicroShield Run PBRWSAMP.MS5), which exceeds allowable dose rate limit of< 0.5 mRem/hr. This means that the dose rate in the sample room would immediately exceed the local area radiation monitor setpoint, and the resulting radiation monitor alarm would alert ~fie chtnr-tist to secure the sam:pliAg 1n*eeess in a saw coRdi~eR and 0vacuate the area immetiitttdy. fic,wevet, m.1 credit is tak.en for the chemist ~;ccul-'.it:1g the.sampling proce££... :i~i+

yersonnt.I to e11ocuo..t-t. +-ht. area.. 1mrnc.c11ate1'1. IJo cxld1+ t!. taxe.n +or +nl 01em1st-secul"'1r1q +.he, wrnp1w113 proc.e.s.s pnor +-o -c.vo..ct.Ao..1ins.

3.0 ACCEPTANCE CRITERIA Two acceptance criteria sets apply to lhe Post-CRDA release from the RCS sample line. The first acceptance criteria are the following NRC regulatory requirement and guidance documents which are applicable to a PBAPS CRDA analysis:

• RG 1.183 (Ref. 9.1, Table 6)

• IOCFR50.67 (Ref. 9.4)

• Standard Review Plan section 15.0.1 (Ref. 9.23)

Dose Acceptance Criteria are:

CRDA Regulatory Dose Limits Dose Type Control Room EAB and LPZ (r~m TEDE) (rem TEDE)

TEDE Dose 5 6.3

CALCULATION NO. PM-1168 REV. No. 0 PAGE NO. 8 of 67 4.0 ASSUMPTIONS Assumptions for Evaluating the Radiological Consequences of a Control Rod Drop Accident (CRDA)

The analysis in this calculation complies with the line-by-line requirements in Regulatory Guide 1.183 including its Appendix C (Ref. 9.1). The assumptions in Reference 9.12, Section 4.0 are applicable to analysis in this calculation with the following additional assumption:

4. l It is assumed that the purging of the RW sample line continues for 60 minutes until the sample valves are closed by a Control Room operator.

[ ,_ _ c_.A_1_~~--,l_JL_A_1_-1_o_N_N_(_>._P_M_-_1_1-;_8~~-------_*=r_~_ _ _ _R_E_:v_._N_o_._o_,______r_A_G_E_N_o_.*_9_o_r*_**-~ 5.0 DESIGN INPUTS 5.1 Gell11eral Considerations 5.1.l Applicability of Prior Ucensing Basis The PBAPS current licensing basis (CLB) for the CRDA event is AST methodology per Amendments 269 and 273 (Ref. 9.9) based on Regulatory Guide 1. I 83 guidance. The analysis in this calculation uses the CLB AST guidance in Regulatory Guide 1.183, Appendix C (Ref. 9 .1 ).

5.1.2 Credit for Engineered Safety Features Credit is taken only for accident mitigation features that are classified as safety-related, are required to be operable by technical specifications, are powered by emergency power sources, and are either automatically actuated or, in limited cases, have actuation requirements explicitly addressed in emergency operating procedures. The safety-related CR emergency ventilation system is not credited for dose mitigation.

5.1.3 Assignment of Numeric Input Values The numeric values that are chosen as inputs to the analyses required by 10 CFR 50.67 (Ref. 9.4) are compatible to AST and TEDE dose criteria and selected with the objective of producing conservative radiological consequences. As a conservative alternative, the limiting value applicable to each portion of the analysis is used in the evaluation of that p011ion.

5.1.4 Meteorology Considerations The ground-level control room atmospheric dispersion factors (X/Qs) for the Reactor Building vent stack release point were previously developed using the PBAPS plant specific meteorology and appropriate regulatory guidance, including the NRC sponsored computer code ARCON96 (Ref. 9.5, Table 5-1). The control room xtQs were accepted by the NRC staff in previous licensing proceedings (Ref. 9.9, Table 3-1).

The ground-level EAB and LPZ xtQs were previously developed using the PBAPS plant specific meteorology and regulatory guidance (Ref. 9.5, Table 1). The off-site xtQs were accepted by the NRC staff in previous licensing proceedings (Ref. 9.9, Tables 3-2 and 3-3).

5.2 Accident-Specific Design Inputs/Assumptions The design inputs/assumptions utilized in the EAB, LPZ, and CR habitability analyses are listed in the following sections. The design inputs are compatible with the AST and TEDE dose criteria. Assumptions are consistent with identified in Appendix C of RG l.183 (Ref. 9.1). The design inputs assumptions in the following sections represent the as-built design of the plant

CALCULATION NO. PM-1168 REV. No. 0 PAGE N0.10 of 67 Design Input Parameter Value Assigned Reference 5.3

• CRDA Parameters 5.3.1 Source Term 5.3.1.1 Rated power level 3,293 MW1 (Original) 9.3, Section 1.1 Item #4, 3,951 MW1 (LPU) and Section 3.2.1 Item# 1 4,030 MWt used in analysis (Includes 2% uncertainty) 5.3.1.2 Isotopic Core Inventory In Ci/MWt at 4,030 MWt 9.3, Appendix B Isotope Activity Isotope Activity Isotope Activity KR-83M 3.848E+03 I-134 6.179E+04 RB-86 6.473E+Ol KR-85 3.658E+02 I-135 5.198E+04 RB-88 2.408E+o4 KR-85M 8.555E+03 XE-131M 3.024E+02 CS-134 6.832E+03 KR-87 l.686E+04 XE-133 5.488E+04 CS-136 l.933E+03 KR-88 2.379E+04 XE-133M l.714E+03 CS-137 4. I 18E+03 I-131 2.704E+04 XE-135 2.140E+04 CS-138 5.270E+04 I-132 3.901E+04 XE-135M l.081E+04 I-133 5.564E+04 XE-138 4.815E+04 5.3.1.3 Radionuclide Composition Group Elements 9.1, Section 3.4, Table 5 Noble gases Xe, Kr Halogens I, Br Alkali metals Cs, Rb 5.3.1.4 Number of fuel rods in 85.6 9.12, Section 5.3.l.4 fuel assembly 5.3.1.5 Damaged fuel rods:

Breached Fuel Rods 1200 9.12, Section 5.3.l.5 Melted Fuel Rods 5.0% of the breached fuel rods Conservative bounding value melted 5.3.1.6 Number of fuel assemblies 764 9.12, Section 5.3.1.6 in core 5.3.1.7 Radial peaking factor 1.70 9.12, Section 5.3.1.10 5.3.1.8 Sample purge rate 500 cc/min 9.10, Section 8.5.6 5.3.1.9 Chemical form of iodine available for release to environment Elemental 97% 9.1, Appendix C, Section 3.6 Organic 3%

5.3.2 Activity Transport (see Figure 1) 5.3.2. l RW sample release rate 0.084 cfm Section 7.1 5.3.2.2 Duration of RW sample 1 hour1.157407e-5 days <br />2.777778e-4 hours <br />1.653439e-6 weeks <br />3.805e-7 months <br />(= 60 minutes) Section 2.1 release 5.3.2.3 Reactor Building Vent Ground level release 9.1, Appendix C, Section 3.4 Stack leak to the atmosphere 5.3.2.4 Reactor coolant volumes: 9.16, Table 2.6-2 RPV liquid volume l I ,790 ft3 RPV attached Piping volume 4,142 rt3

CALCULATION NO. PM-1168 REV. No. 0 PAGE N0.11 of* 67 Design Input Parameter Value Assigned Reference 5.3.2.5 Reactor coolant 532.7uF 9.16, Figure 1-3 temperature (Overpressure protection) 5.3.2.6 RW sample line data Schedule SOS 3/4-inch diameter 9.14, Page 44 Nominal Outside Diameter 1.05" Nominal Inside Diameter 0.742" Wall thickness 0.154" 5.3.2.7 Sample Sink Radiation Zone designation I 9.20.2 Maximum allowable dose rate  ::; 0.5 mRem/hr 9.20.1 5.3.2.8 RW sample volume 0.265 fr' Section 2.1 5.3.2.9 RW sample activity 0.0814 cfm Section 7.1 release rate 5.3.2.10 Reactor coolant volume 15,932 fri Section 7.2 5.3.2.11 RW Iodine and Alkali 0.40 Section 7.3 Metals flashing factor 5.3.2.12 RW sample density 0.754 glee Section 7.3 5.3.2.13 RW activity release point Reactor Building Vent Stack 9.15 5.3.3 Control Room Parameters (see Figure 2) 5.3.3. l CR volume 176,000 fr' 9.17, Attachment 2, page 4 5.3.3.2 CR maximum air inflow 20,600cfm 9.13 rate during CRDA + 500 cfm inleakage Assumed in Item 5.3.3.4 21,100 cfm used in the analysis 5.3.3.3 CR charcoal iodine & 0% removal Not credited in this analysis HEPA particulate filter efficiencies 5.3.3.4 CR Unfiltered Inleakage 500cfm Assumed 5.3.3.5 CR occupancy factors Time (Hr)  % 9.1, Section 4.2.6 0-24 100 24-96 60 96-720 40 5.3.3.6 CR breathing rate 3.5E-04 m5/sec 9.1, Section 4.2.6 5.3.3.7 CR atmospheric dispersion factors for Reactor Building Vent Stack ground level release (X/Qs)

Time (Hr) X/Q (sec/mj) 9.5, Table 5-1 0-2 1.18E-03 2-8 9.08E-04 8-24 4.14E-04 24-96 2.90E-04 96-720 2.26E-04 5.3.4 Site Boundary Release Model Parameters 5.3.4. l EAB atmospheric 9. l lE-04 sec/mJ 9.5, Table 5-1 dispersion factor for ground level release (X/Q)

CALCULATION NO. PM-1168 REV.No. 0 PAGEN0.12of: 67 Design Input Parameter Value Assigned Reference 5.3.4.2 LPZ Atmospheric dispersion factors for ground level release (X/Qs)

Time (Hr) XJQ (sec/mj) 9.5, Table 5-1 0-2 l.38E-04 2-8 5.SlE-05 8-24 3.77E-05 24-96 l.48E-05 96-720 4.15E-06 5.3.4.3 EAB breathing rate 3.5E-04 mJ/sec 9.1, Section 4.1.6 5.3.4.4 LPZ breathing rates Time (Hr) (mj/sec) 9.1, Section 4.1.6 0-8 3.5E-04 8-24 1.8E-04 24-720 2.3E-04

CALCULATION NO. PM-1168 REV.No. 0 PAGE N0.13 of 67 6.0 COMPUTER CODES & REGULATORY COMPLIANCE 6.1 Computer Codes All computer codes used in this calculation have been approved for use with appropriate Verification and Validation (V & V) documentation. Computer codes used in this analysis include:

• RADTRAD 3.03 (Ref. 9.2): This is an NRC-sponsored code approved for use in determining control room and offsite doses from releases due to reactor accidents. This code was used by most of the AST license amendments that have been approved by the NRC. A rigorous high quality code qualification process was adopted to develop and procure the code by testing of the program elements, verification of input/output files, and examination of design specification.

Therefore, the RADTRAD3.03 computer code is considered to be qualified to comply with the quality assurance requirements of 10 CFR50, Appendix Band it can be safely used to perform the design basis accident analyses. This code was used by EXELON in various AST license amendments, which are approved by the NRC. Therefore, the code is considered validated to be used for the PBAPS AST analysis.

The Exelon V&Vof the RADTRAD3.03 code is documented as DTSQA Number EX0004754 and is classified as SQA Level AA per IT-AA-101 (Ref. 9.11).

• MicroShield 5.05 (Ref. 9.2 l): A commercially available and accepted code used to determine dose rates at various source-receptor combinations. Several runs were made at various times during the LOCA since the source strength varies over time.

The Exelon V& V of the MicroShield 5.05 code is documented as DTSQA Number EXOOO 1136 (Ref. 9.22).

6.2 Regulatory Compliance As discussed in Section 4.0, Assumptions, the analysis in this calculation complies with the line-by-line requirements in Regulatory Guide 1.183 including its Appendix C (Ref. 9.1).

CALCULATION NO. PM-1168 REV. No. 0 r*- PAG.E NO. 14 of 67 7.0 CALCULATIONS 7.1 Reactor Water Sample Activity Release Rate A I Ao= exp[- At]

Where:

Ao= Initial Activity in RW Sample A = Final Activity in RW Sample A= Removal Rate (volume/hr) t = Removal Time (hr)

Assuming that 99% of the reactor coolant activity within a reactor water sample volume of 1.06 ft 3 is released to the main condenser within l hour (per Section 2.1):

A I Ao= 0.01 =exp[- At]

Therefore, ln(0.01)=-'At

-4.605 = - 'A x 1 hr A::::: (4.605) I I hr= 4.065 volume/hr= 4.605 x (l.06 ft:3 I hr) I 60 min/hr= 0.0814 cfm 7.2 Total Reactor Coolant Volume Reactor coolant volume in Reactor Pressure Vessel (RPV) = 11,790 ft3 (Ref. 9.16, Table 2.6-2)

Reactor coolant volume in RPV attached piping= 4, 142 ft3 (Ref. 9.16, Table 2.6-2)

Total reactor coolant volume= 11,790 ft 3 + 4,142 ft 3 = 15,932 ft 3 used in Table 3 7.3 Post-CRDA Airborne Mass of RW Sample Reactor Vessel dome temperature= 532.7° F (Section 5.3.2.5)

The non-safety related sample chillers are not assumed to function after a CRDA, and therefore, the RW liquid is conservatively assumed to be the same as the vessel dome temperature, 532.7°F, which results a considerably large amount iodine that becomes airborne from the RW sample.

Since the temperature of the RW liquid exceeds 2 I 2°F, the fraction of iodine and alkali metals in the RW liquid that becomes airborne is assumed equal to the fraction of the leakage that flashes to vapor.

The flashing fraction (FF) is calculated using the constant enthalpy method (Ref. 9.1, Appendix A, Section 5 .4) as follows:

FF : : : (h - h1iquid) I (hsteam - hliquid)

Where: his enthalpy of the RW liquid at system design temperature and pressure hliquid is the enthalpy of water at saturation conditions ( 14. 7 psi a, 212°F) hsteam is the enthalpy of steam at saturation conditions (14. 7 psi a, 2 l 2°F)

RW Liquid enthalpy of@ 532.7° F:::: 527.63 BTU/lb (Ref. 9.18, page 182)

CALCULATION NO. PM-1168 REV.No. 0 PAGE NO. 15 of: 67 Saturated Steam enthalpy@ 14.7 psia and 212° F = 1150.5 BTU/lb (Ref. 9.18, page 184)

Saturated Water enthalpy@ 14.7 psia and 212° F = 180.17 BTU/lb (Ref. 9.18, page 184)

Substituting, FF=(527.63- l80.17)/(ll50.5-180.17)=0.358 For conservatism, a value of 0.40 or 40% is used in Table 3.

RW Liquid specific volume = 0.021251 ft 3/lb RW Liquid density= 1 I RW Liquid specific volume= (0.021251 ft 3/lb)" 1

= 47.057 lb/ft3 x (453.6 gm/lb) x (30.48 cm/ft)" 3 = 0.754 glee 7.4 Sample Volume in RW Sample Line 3/4" RW Sample Pipe Nominal Outside Diameter (OD)= 1.05" (Ref. 9.14, Page 44) 3/4" RW Sample Pipe Inside Diameter (ID)= 0.742" (Ref. 9.14, Page 44)

Volume of Sample in a 20 feet long sample line

= 1t/4 x ID2 x 20ft=1t/4 x (0.742/12 ft/inch) 2 x 20 ft= 0.06 ft 3

CALCULATION NO. PM-1168 REV. No. 0 PAGE NO. 16 of 67 RESULTS

SUMMARY

& CONCLUSIONS Results Summary:

The resulting doses from the post-CRDA RW sample line release are summarized in the following table:

Post-CRDA Post-CRDA TEDE Dose (Rem)

Activity Release Receptor Location Path Control Room EAB LPZ Design Basis CRDA (1) 1.77 2.04 0.3S .

RW Sample Release 0.290 0.286 0.043 Total Dose 2.06E+OO 2.33E+OO 3.93E-Ol Allowable TEDE Limit S.OOE+OO 6.30E+OO 6.30E+OO RADTRAD Computer Run No.

RW Sample Release PCRDASMPOO.oO PCRDASMPOO.oO PCRDASMPOO.oO (1) From Reference 9.12, Section 8.1 - Main & Gland Seal Condenser Leakage Case 8.2 The resulting post-CRDA whole body gamma dose rate in the sampling area is summarized in the following table.

Post-CRDA Dose Rate Activity in RW Calculated Dose Rate Allowable Dose Rate Limit Sample Line Area mRem/hr mRem/hr Whole Body Gamma Dose Rate at I foot 27250 :5 2.5 from RW sample line 8.3

Conclusions:

The comparison of resulting doses with the licensing basis CRDA doses in Section 8.1 indicates that the post-CRDA EAB, LPZ, and CR doses due to a reactor water sample line release are a fraction (less than 20 percent) of the CRDA doses for the most conservative case of continuous purging of RW sample line for I hour.

The analysis result presented in Section 8.2 indicates that the post-CRDA contact dose rate of the RW sample line in the sampling area is expected to instantly exceed the radiation zone allowable dose rate limit, and the resulting radiation monitor alarm would alert the chemist to secure the sampling process in a safe condition and evacuate the area immediately.

A Control Room operator action item to close the RW sample valves following a CRDA should be captured in the CRDA "Emergency Operation Instructions (EOis)."

c CALCULATION NO. PM-1168 REV.No. 0 PAGE NO. 17 of* 67 9.0 REJi'ERENCES L U.S. NRC Regulatory Guide l.183, "Alternative Radiological Source Terms for Evaluating Design Bas\s Accidents. at Nuclear Power Reactors", July 2000

2. S.L. Humphreys et al., NUREG/CR-6604 (including Supplements 1 and 2), "RADTRAD: A Simplified Model for Radionuclide Transport and Removal and Dose Estimation," (originally published December 1997; Supplement l dated June 8, 1999, and Supplement 2 dated October 2002).

3. PEAM-EPU-63; GEHProject Task Report0000-0117-7472-R2 (DRF0000-0105-2456 Rcvision2) for Peach Bottom Atomic Power Station Units 2 and 3; Extended Power Uprate Task T0802, Revision 2, "Core Source Term", January 2011

4. 10 CFR 50.67, "Accident Source Term."

5. PBAPS Calculation PM-1055, Revision J, "Calculation of Alternative Source Term (AST) Onsite and Offsite X.JQ Values".

6. General Electric (GE) document NED0-31400A, October l 992, "Safety Evaluation for Eliminating The Boiling Water Reactor Main Steam Isolation Valve Closure Function and Scram Function of The Main Steam Line Radiation Monitor."

7. Federal Guidance Repmt 11, EPA-520/1-88-020, Environmental Protection Agency.

8. Federal Guidance Report 12, EPA~402-R-93-08 l, Environmental Protection Agency.

9. Peach Bottom Atomic Power Station Amendment Nos. 269 and 273 to Renewed Facility Operating License Nos. DPR-44 and DPR-56 for the Peach Bottom Atomic Power Station (PBAPS), Units 2 and 3.

RE: Application Of Alternative Source Term Methodology; September 5, 2008 (ADAMS Accession Number ML082320406).

10. PBAPS Chemistry Procedure No. CH-407, Revision 8, "Sampling of Reactor Water."

l 1. Exelon DTSQA Number EX0004754for RADTRAD V&V VersionJ.03.

12. PBAPS Calculation PM-1057, Revision 5, "EAB, LPZ, and CR Doses due to Control Rod Drop Accident (CRDA) (Task T0901)."

• 13. PBAPS Drawing 6280-M-884, Sheet 2, "QAD Diagram Control Room HVAC", Revision 2.

14. PBAPS Specification No. M-00300, *Revision 18, "Specification for Piping Materials, Instrument Piping Standards, and Valve Classifications for PBAPS Units 2 & 3."

15. PBAPS P&I Diagram No. M-388, Revision 35, "Reactor Building Ventilation Flow Diagram."

16. NED0-33566, Revision 0, "Safety Analysis Report for EXELON Peach Bottom Atomic Power Station Units 2 & 3 Constant Pressure Power Uprate."

17. Bechtel Letter No. BLP 22066, 05/18/1982, "Design Review of Plant Shielding."

18. ASME Steam Tables, Sixth Edition.

EXELON Procedure No. GP-15, Revision 7, "Local Evacuation."

20. PBAPS UFSAR 20.l UFSAR Section 12.3.3, Revision 17, "Radiation Zoning and Access Control" 20.2 UFSAR Figure 12.3.4, Revision 12, "RADIATION ZONES- UNITS 2AND3; EL 165FT 0 IN (IN OPERATION)"

21. MicroShield Computer Code, V&V Version 5.05, Grove Engineering.

CALCULATION NO. PM-1168 REV. No. 0 PAGE NO. 18 of 67

22. Exelon DTSQA Number EXOOOl 136 for MicroShield V&V Version 5.05

23. NUREG-0800, Standard Review Plan, "Radiological Consequence Analyses Using Alternative Source Terms," SRP 15.0. l, Revision 0, July 2000.

24. P&ID Diagrams:

24. l 6280-M-326, Sheet 2, Revision 37, "Process Sampling."

24.2 6280-M-326, Sheet 10, Revision 52, "Process Sampling."

CALCULATION NO. PM-1168 REV.No. 0 PAGE NO. 19 of 67 rn.o TABLES Table l Post-CRDA Activity Im Damaged Fuel Rods Core Core Radial Average Total Number of Total Peak Isotope Isotopic Thermal Peaking Number Number Damaged Core Activity Inventory Power Factor of Fuel of Fuel Fuel In Damaged (Ci/MWt) Level Rods Per Rods Rods Fuel Rods (MWt) Bundle In Core ByCRDA (Ci)

A B c D E=D*764 F G:::::(A *B*C*F)/E I-131 2.704E+04 4030 1.7 85.6 65398 1200 3.399E+06 I-132 3.901E+04 4030 1.7 85.6 65398 1200 4.904E+06 f- I 33 5.564E+04 4030 1.7 85.6 65398 1200 6.994E+06 l-134 6.179E+04 4030 1.7 85.6 65398 1200 . 7.768E+06 I- t:l5 5.198E+04 4030  !.7 85.6 65398 1200 6.534E+06 KR-83M 3.848E+03 4030 1.7 85.6 65398 1200 4.837E+05 KR- 85 3.658E+02 4030 1.7 85.6 65398 1200 4.598E+04 KR- 85M 8.555E+03 4030 1.7 85.6 65398 1200 l.075E+06 KR-87 l.686E+04 4030 1.7 85.6 65398 1200 2.l 19E+06 KR-88 2.379E+04 4030 1.7 85.6 65398 1200 2.991E+06 XEl3IM 3.024E+02 4030 l.7 85.6 65398 1200 3.801E+04 XE-133 5.488E+04 40'.'0 1.7 85.6 65398 1200 6.899E+06 XE-133M l.714E+03 4030 1.7 85.6 65398 1200 2.l55E+05 XE-!35 2.140E+04 4030 1.7 85.6 65398 1200 2.690E+06 XE-l35M l.08 IE+04 4030 1.7 85.6 65398 1200 l.359E+06 XE-138 4.815E+04 4030 1.7 85.6 65398 1200 6.053E+06 RB-86 6.473E+OI 4030 1.7 85.6 65398 1200 8. I 37E+03 RB-88 2.408E+04 4030 l.7 85.6 65398 1200 3.027E+06 CS-134 6.832E+03 4030 1.7 85.6 65398 1200 8.588E+05 CS-136 1.933E+03 4030 1.7 85.6 65398 1200 2.430E+05 CS-137 4. I 18E+03 *-**- .. 4030 1.7 85.6 65398 1200 5.177E+05

-~--*

CS-138 5.270E+04 4030 1.7 85.6 65398 1200 6.625E+06 A From Reference 9.3, Appendix B B From Reference 9.12, Section 5.3.1. l C From Reference 9.12, Section 5.3.1.10 D From Reference 9.12, Section 5.3.1.4 E From Reference 9.12, Section 5.3. l .6 F From Reference 9.12, Section 5.3. l .5

CALCULATION NO. PM-1168 REV.No. 0 PAGE NO. 20 of 67 Table 2 Total CRDA Activity Released To Reactor Water Total Peak Gap Activity Total Gap Reactor Post-CRDA Isotope Core Activity Release Activity Coolant Reactor In Damaged Fraction Released To Volume Coolant Fuel Rods From Damaged Reactor Concentration Fuel Rods Water (Ci) (Ci) (Ci) (ft3) <cvre)

A B C=AxB D E=C/D I-131 3.399E+06 0.1200 4.079E+05 2.560E+OI 1-132 4.904E+06 0.1200 5.885E+05 3.694E+Ol 1-133 6.994E+06 0.1200 8.393E+05 5.268E+Ol 1-134 7.768E+06 0.1200 9.321E+05 5.851E+OI f-135 6.534E+06 0.1200 7.841E+05 4.922E+OI KR-83M 4.837E+05 0.1450 7.014E+04 4.403E+OO KR- 85 4.598E+04 0.1450 6.668E+03 4.185E-Ol KR- 85M 1.075E+06 0.1450 l.559E+05 9.788E+OO KR- 87 2.l 19E+06 0.1450 3.073E+05 1.929E+Ol KR-88 2.991E+06 0.1450 4.336E+05 2.722E+OI XEl31M 3.801E+04 0.1450 5.512E+03 3.460E-OJ l.5932E+04 XE-133 6.899E+06 0.1450 l.OOOE+06 6.279E+OI XE-133M 2.155E+05 0.1450 3.124E+04 1.961E+OO XE-135 2.690E+06 0.1450 3.901E+05 2.448E+OI XE-135M l.359E+06 0.1450 l.970E+05 l.237E+Ol XE-138 6.053E+06 0.1450 8.777E+05 5.509E+OI RB-86 8.137E+03 0.1265 l.029E+03 6.461E-02 RB-88 3.027E+06 0.1265 3.829E+05 2.404E+Ol CS-134 8.588E+05 0.1265 l.086E+05 6.819E+OO CS-136 2.430E+05 0.1265 3.074E+04 l.929E+OO CS-137 5.177E+05 0.1265 6.549E+04 4.1 IOE+OO CS-138 6.625E+06 0.1265 8.380E+05 5.260E+Ol A From Table 1 B From Reference 9.12, Section 7.1 D From Section 7 .2

CALCULATION NO. PM-1168 REV. No. 0 PAGE NO. 21 of' 67 Table 3 Post*CRDA Reactor Water Sample Activity Post-CRDA Reactor Flashing Post-CRDA Isotope Reactor Water Fraction Reactor Wat er Sample Coolant Sam1Jle Activity Concentration Volume Activity Available For Release (Ci!ft3) (ft3) (Ci) (Ci) c D:::::AxH

- I-131 A

2.560E+01

- B

• -0.40 2.714E+Ol E=CxD l .086E+Ol 1-132 3.694E+Ol 0.40 3.915E+Ol l.566E+Ol 1-133 5.268E+Ol 0.40 5.584E+OI 2.234E+Ol I-134 5.851E+OI 0.40 6.202E+OI 2.481E+OI 1-135 4.922E+OI 0.40 5.217E+Ol 2.087E+OI KR-83M 4.403E+OO 1.00 4.667E+OO 4.667E+OO KR- 85 4. l85E-OI l.00 4.436E-Ol 4.436E-O I KR- 85M 9.788E+OO l.00 l.038E+OI l.038E+OI KR- 87 I.929E+OI 1.00 2.045E+OI 2.045E+Ol KR-88 2.722E+Ol 1.00 2.885E+Ol 2.885E+Ol XEl31M 3.460E-01 1.00 3.667E-OI 3.667E-OI 1.06 XE-133 6.279E+OI LOO 6.656E+OI 6.656E+Ol XE-133M l.961E+OO 1.00 2.079E+OO 2.079E+OO XE-135 2.448E+Ol 1.00 2.595E+Ol 2.595E+01 XE-135M l.237E+Ol 1.00 l.311 E+Ol 1.31 lE+OI XE-138 5.509E+Ol 1.00 5.839E+Ol 5.839E+OI RB-86 6.461E-02 0.40 6.849E-02 2.739E-02 RB-88 2.404E+01 0.40 2.548E+OI l.019E+OI CS-134 6.819E+OO 0.40 7.228E+OO 2.89lE+OO CS-136 l.929E+OO 0.40 2.045E+OO 8.181E-01

---

-* ***W-~

CS-137 4.l IOE+OO 0.40 4.357E+OO 1.743E+OO CS-138 5.260E+Ol 0.40 5.576E+Ol 2.230E+Ol A From Table 2 B From Section 2.1 C == 40% of Iodine & Alkali Metal Activity From RW Sample Becomes (Flashes) Airborne - Section 7 .3 C = !00% of NG Activity From RW Sample Becomes (Flashes) Airborne - Section 7.3

CALCULATION NO. PM-1168 REV. No. 0 PAGE NO. 22 of; 67 Table 4 Post-CRDA A<:tivity in RW Sample Line (20 foot pipe length)

Post-CRDA Reactor Post-CRDA Isotope Reactor Water Reactor Coolant Sample Line Water Concentration Volume Sample Line Activity (Ci/ft3) (ftJ) (Ci)

A B C=AxB 1-131 2.560E+OI l.536E+OO l-132 3.694E+OI 2.216E+OO I-133 5.2688+01 3.161E+OO 1-134 5.85 IE+OI 3.5 IOE+OO I-135 4.922E+OI 2.953E+OO KR-83M 4.403E+OO 2.642E-Ol KR- 85 4.185E-Ol 2.51 lE-02 KR- 85M 9.788E+OO 5.873E-OI KR- 87 l.929E+OI J.157E+OO KR-88 2.722E+OI l.633E+OO XE131M 3.460E-01 2.076E-02 0.060 XE-133 6.279E+Ol 3.767E+OO XE-133M l.961E+OO i. l77E-Ol XE-135 2.448E+Ol 1.4698+00 XE-135M l.237E+01 7.421E-OI XE-138 5.509E+OI 3.305E+OO RB-86 6.461E-02 3.8778-03 RB-88 2.404E+Ol l.442E+OO CS-134 6.819E+OO 4.092E-OJ

--CS-136 CS-137 l.929E+OO 4.1 IOE+OO 1.1588-0 I 2.466E-OI CS-138 5.260E+OI 3.156E+OO A From Table 2 B From Section 7.4

CALCULATION NO. PM-1168 REV. No. 0 PAGE NO. 23 of 67 11.0 FIGURES E

N v

I RWSample

=

v 1.06 rt3 I 0.0814 cfm :5 1.0 hr I --

R I To CR, EAB, LPZ I

0 N

M E

N T

Figure 1: Post-CRDA RW Sample Release

CALCULATION NO. PM-1168 REV. No. 0 PAGE NO. 24 of .67 0 - 720 hrs 21,100 cfm E

N v

I R Control Room RWSample Release 0 v =176,000 ft3 N

M E

N T

0 - 720 hrs 20,600 cfm

+ 500 cfm Unfiltered inleakage Figure 2 - PBAPS Control Room RADTRAD Nodalization

CALCULATION NO. PM-1168 REV.No. 0 PAGE NO. 25 of: 67 12.0 AFFECTED DOCUMENTS The following documents will be either superseded or revised:

Document to be superseded

~ see ECR 1'3- OD4Cf4

~!t

~

Documents to be revised:

13.0 ATTACHMENTS

13. l RADTRAD Output File: PCRDASMPOO.oO 13.2 MicroShield Output File: PBRWSAMP.MS5 13.3 RADTRAD Nuclide Inventory File: PBCRDASMPOO_def.txt 13.4 RADTRAD Release Fraction and Timing File: pbcrda_rft.txt 13.5 RADTRAD Dose Conversion Factor File: pbcrda_fgl 1&12.txt

CALCULATION NO. PM*ll68 REV. No. 0 PAGE NO. 26 of: 67 Attachment 13.l RADTRAD Output File: PCRDASMPOO.oO RADTRAD Version 3.03 (Spring 2001) run on 5/21/2014 at 18:11:52 File information Plant file G:\Radtrad 3.03\Input\PM-1168\PCRDASMPOO.psf Inventory file = G:\Radtrad 3.03\Defaults\PBCRDASMPOO_def.txt Release file g:\radtrad 3.03\defaults\pbcrda_rft.txt Dose Conversion file g:\radtrad 3.03\defaults\pbcrda_fgll&l2.txt

1. # # tt # # # # # # # # #

Radtrad 3.03 4/15/2001 PBAPS Post-CRDA EAB, LP.Z, & CR Doses Due To Release from RW Sample With Iodine Flashing Factor of 40% and Using Guidance in RG 1.183, Appendix C Nuclide Inventory File:

G:\Radtrad 3.03\Defaults\PBCRDASMPOO_def .txt Plant Power Level:

1.0000E+OO Compartments:

3 Compartment 1:

RCS Sample 3

l.0600E+OO 0

0 0

0 0

Compartment 2:

Environment 2

O.OOOOE+OO 0

0 0

0 0

Compartment 3:

CALCULATION NO. PM-1168 REV. No. 0 PAGE NO. 27 of: 67 Control Room 1

1.7600E+05 0

0 0

0 0

Pathways:

3 Pathway 1:

Environment to Control Room 2

3 2

Pathway 2:

Control Room Exhaust to Environment 3

2 2

Pathway 3:

RCS Sample to Environment 1

2 2

End of Plant Model File Scenario Description Name:

Plant Model Filename:

Source Term:

1 1 l.OOOOE+OO g:\radtrad 3.03\defaults\pbcrda_fgll&l2.txt g:\radtrad 3.03\defaults\pbcrda_rft.txt O.OOOOE+OO 1

O.OOOOE+OO 9.?000E-01 3.0000E-02 1.0000E+OO Overlying Pool:

0 O.OOOOE+OO 0

0 0

0 Compartments:

3 Compartment 1:

0 1

0 0

0 0

0 0

0 Compartment 2:

L-[_-_*-_ _c_A_L_c_u_L_A_l_'IO_N_N_o_._r_M_-_11_6,_8____,___ _ _ _R_E_'V_._N_o._o_ _ _ _..........;,___1:~A~(,_'-E~N-O-.2-;:~*;--~-7-J 0

1 0

0 0

0 0

0 0

Compartment 3:

0 1

0 0

0 0

0 0

0 Pathways:

3 Pathway 1:

0 0

0 0

0 1

2 O.OOOOE+OO 2 .1100E+04 O.OOOOE+OO 0.0000E+OO O.OOOOE+OO

'7.2000E+02 O.OOOOE+OO O.OOOOE+OO 0.0000E+OO O.OOOOE+OO 0

0 0

0 0

0 Pathway 2:

0 0

0 0

0 1

2 O.OOOOE+OO 2 .1100E+04 1.0000E+02 1.0000E+02 1.0000E+02 7.2000E+02 O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO 0

0 0

0 0

0 Pathway 3:

0 0

0 0

CALCULATION NO. PM-.1168 UEV. No. 0 PAGE NO. 2~ of:. ~~

0 1

2 O.OOOOE+OO 8.1400.E-02 O.OOOOE+OO O.OOOOE+OO 0.0000E+OO 1.0000E+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO 0.0000E+OO 0

0 0

0 0

0 Dose Locations:

3 Location 1:

Exclusion Area Boundary 2

1 2

0.0000E+OO 9. llOOE-04 7.2000E+02 O.OOOOE+OO 1

2 O.OOOOE+OO 3.5000E-04 7.2000E+02 0. OOOOE-i*OO 0

Location 2:

Low Population Zone 2

1 6

0. 00.00E+OO 1.3800E-04 2.0000E+OO 5.8100E-05 8.0000E+OO 3.7700E-05 2 .4000E+Ol 1. 4800E-05 9.6000E+01 4.1500E-06 7.2000E+02 O.OOOOE+OO 1

4 O.OOOOE+OO 3.5000E-04 8.0000E+OO 1.SOOOE-04 2.4000E+Ol 2.3000E-04 7.2000E+02 O.OOOOE+OO 0

Location 3:

Control Room 3

0 1

2 O.OOOOE+OO 3.SOOOE-04 7.2000E+02 O.OOOOE+OO 1

4 0.0000E+OO 1.0000E+OO 2.4000E+01 6.0000E-01 9.6000E+Ol 4.0000E-01 7.2000E+02 O.OOOOE+OO Effective Volume Location:

CALCULATION NO. PM-1168 REV. No. 0 PAGE NO. 30 of: 67 1

6 O.OOOOE+OO l.1800E-03 2.0000E+OO 9.0800E-04 8.0000E+OO 4.1400E-04 2.4000E+Ol 2.9000E-04 9.6000E+Ol 2.2600E-04 7.2000E+02 O.OOOOE+OO Simulation Parameters:

6 O.OOOOE+OO l.OOOOE-01 2.0000E+OO 5.0000E-01 8.0000E+OO l.OOOOE+OO 2.4000E+Ol 2.0000E+OO 9.6000E+Ol 8.0000E+OO 7.2000E+02 O.OOOOE+OO Output Filename:

G:\Radtrad 3.ol9 1

1 1

0 0

End of Scenario File

CALCULATION NO. PM-1168 REV. No. 0 PAGE NO. 31 of 67 RADTRAD Version 3.03 (Spring 2001) run on 5/21/2014 at 18:11:52 Plant Description Number of Nuclides 60 Inventory Power= 1.0000E+OO MWth Plant Power Level 1.0000E+OO MWth Number of compartments = 3 Compartment information Compartment number 1 (Source term fraction = 1.0000E+OO

)

Name: RCS Sample Compartment volume l.0600E+OO (Cubic feet)

Compartment type is Normal Pathways into and out of compartment 1 Exit Pathway Number 3: RCS Sample to Environment Compartment number 2 Name: Environment Compartment type is Environment Pathways into and out of compartment 2 Inlet Pathway Number 2: Control Room Exhaust to Environment Inlet Pathway Number 3: RCS Sample to Environment Exit Pathway Number 1: Environment to Control Room Compartment number 3 Name: Control Room Compartment volume = 1.7600E+05 (Cubic feet)

Compartment type is Control Room Pathways into and out of compartment 3 Inlet Pathway Number 1: Environment to Control Room Exit Pathway Number 2: Control Room Exhaust to Environment Total number of pathways 3

CALCULATION NO. PM-1168 REV.No. 0 PAGE NO. 32 of. , 67 RADTRAD Version 3.03 (Spring 2001) run on 5/21/2014 at 18:11:52 Scenario Description Radioactive Decay is enabled Calculation of Daughters is enabled Release Fractions and Timings GAP EARLY IN-VESSEL LATE R~LEASE RELEASE MASS 0.003600 hr 0.0000 hrs 0.0000 hrs (gm)

NOBLES l.OOOOE+OO O.OOOOE+OO O.OOOOE+OO l.510E-03 IODINE l.OOOOE+OO O.OOOOE+OO O.OOOOE+OO 1.157E-04 CESIUM l.OOOOE+OO O.OOOOE+OO O.OOOOE+OO 2.229E-02 TELLURIUM O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOE+OO STRONTIUM O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOE+OO BARIUM O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOE+OO RUTHENIUM O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOE+OO CERIUM O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOE+OO LANTHANUM O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOE+OO Inventory Power "" 1. MWt Nuclide Group Specific half Whole Body Inhaled Inhaled Name Inventory life DCF Thyroid Effective (Ci/MWt) ( s) (Sv-m3/Bq-s) (Sv/Bq) (Sv/Bq)

Kr-83m 1 4.667E+OO 6.588E+03 l.500E-18 O.OOOE+OO O.OOOE+OO Kr-85 1 4.436E-01 3.383E+08 l.190E-16 O.OOOE+OO O.OOOE+OO Kr-85m 1 1.038E+Ol 1.613E+04 7.480E-15 O.OOOE+OO O.OOOE+OO Kr-87 1 2.045E+Ol 4.578E+03 4.120E-14 O.OOOE+OO O.OOOE+OO Kr-88 1 2.885E+Ol l.022E+04 1. 020E-13 O.OOOE+OO O.OOOE+OO Rb-86 3 2.739E-02 1. 612E+06 4.810E-15 1.330E-09 1. 790E-09 Rb-88 3 1.019E+01 1.068E+03 3.360E-14 1.370E-12 2.260E-11 I-131 2 1.086E+Ol 6.947E+05 l.820E-14 2.920E-07 8.890E-09 I-132 2 1.566E+Ol 8.280E+03 l.120E-13 1.740E-09 1.030E-10 I-133 2 2.234E+Ol 7.488E+04 2.940E-14 4.860E-08 l.580E-09 I-134 2 2.481E+Ol 3.156E+03 1.300E-13 2.880E-10 3. 550E-ll I-135 2 2.087E+Ol 2.380E+04 8.294E-14 8.460E-09 3.320E-10 Xe-13lm 1 3.367E-01 1.028E+06 3.890E-16 O.OOOE+OO O.OOOE+OO Xe-133 1 6.656E+01 4.532E+05 1. 560E-15 O.OOOE+OO O.OOOE+OO Xe-133m 1 2.079E+OO 1.890E+05 l.370E-15 O.OOOE+OO O.OOOE+OO Xe-135 1 2.595E+Ol 3.272E+04 1.190E-14 O.OOOE+OO O.OOOE+OO Xe-135m 1 1.311E+Ol 9.174E+02 2.040E-14 Q,QOOE+OO O.OOOE+OO Xe-138 1 5.839E+Ol 8.502E+02 5.770E-14 O.OOOE+OO O.OOOE+OO Cs-134 3 2.891E+OO 6.507E+07 7.570E-14 1.llOE-08 1. 250E-08 Cs-136 3 8.181E-Ol 1.132E+06 l.060E-13 l.730E-09 l.980E-09 Cs-137 3 1.743E+OO 9.467E+08 2.725E-14 7.930E-09 8.630E-09 Cs-138 3 2.230E+Ol l.932E+03 1.210E-13 3.570E-12 2. 740E-11 Nuclide Daughter Fraction Daughter Fraction Daughter Fraction Kr-85m Kr-85 0.21 none 0.00 none 0.00 Kr-87 Rb-87 1. 00 none 0.00 none 0.00 Kr-88 Rb-88 1. 00 none 0.00 none 0.00 I-131 Xe-131m 0.01 none 0.00 none 0.00

I-133 Xe-133m 0. 03 Xe-133 0.97 none 0.00 I-135 Xe-135m 0.15 Xe-* 13 5 0.85 none 0.00 Xe-133m Xe-133 1. 00 none 0.00 none 0.00 Xe-135 Cs-135 1. 00 none 0.00 none o.oo Xe-135m Xe-*135 1. 00 none 0.00 none 0.00 Xe-138 Cs-138 1. 00 none 0.00 none 0.00 Cs-137 Ba-137m 0.95 none 0.00 none 0.00 Iodine fractions Aerosol O.OOOOE+OO Elemental 9.7000E-01 Organic 3.0000E-02 COMPARTMENT DATA Compartment number 1: RCS Sample Compartment number 2: Environment Compartment number 3: Control. Room PATHWAY DATA Pathway number 1: Environment to Control. Room Pathway Filter: Removal. Data Time (hr) Flow Rate Filter Efficiencies (%)

(cfm) Aerosol Elemental Organic O.OOOOE+OO 2 .1100E+04 O.OOOOE+OO O.OOOOE+OO 0.0000E+OO 7.2000E+02 O.OOOOE+OO O.OOOOE+OO 0.0000E+OO O.OOOOE+OO Pathway number 2: Control Room Exhaust to Environment Pathway Filter: Removal Data Time (hr) Flow Rate Filter Efficiencies (%)

(cfm) Aerosol Elemental Organic O.OOOOE+OO 2 .1100E+04 l.OOOOE+02 1.0000E+02 1.0000E+02 7.2000E+02 0.0000E+OO 0.0000E+OO O.OOOOE+OO 0.0000E+OO Pathway number 3: RCS to Environment Pathway Filter: Removal Data Time (hr) Flow Rate Filter Efficiencies (%)

(cfm) Aerosol Elemental Organic O.OOOOE+OO 8. HOOE-02 O.OOOOE+OO O.OOOOE+OO 0.0000E+OO 1.0000E+OO O.OOOOE+OO 0.0000E+OO O.OOOOE+OO 0.0000E+OO LOCATION DATA Location Exclusion Area Boundary is in compartment 2 Location X/Q Data Time (hr) X/Q (s

• m"-3)

O.OOOOE+OO 9.llOOE-04 7.2000E+02 0.0000E+OO

CALCULATION NO. PM-1168 REV. No. 0 PAGE NO. 34 of 67 Location Breathing Rate Data Time (hr) Breathing Rate (mA3

• secA-1)

O.OOOOE+OO 3.SOOOE-04 7.2000E+02 O.OOOOE+OO Location Low Population Zone is in compartment 2 Location X/Q Data Time (hr) X/Q (s

• mA-3)

O.OOOOE+OO 1.3800E-04 2.0000E+OO 5.BlOOE-05 8.0000E+OO 3. 7700E-05 2.4000E+Ol 1.4800E-05 9.6000E+Ol 4.lSOOE-06 7.2000E+02 O.OOOOE+OO Location Breathing Rate Data Time (hr) Breathing Rate (mA3

• secA-1)

O.OOOOE+OO 3.SOOOE-04 8.0000E+OO 1.SOOOE-04 2.4000E+Ol 2.3000E-04 7.2000E+02 O.OOOOE+OO Location Control Room is in compartment 3 Location X/Q Data Time (hr) X/Q (s

• mA-3)

O.OOOOE+OO 1.1800E-03 2.0000E+OO 9.0SOOE-04 8.0000E+OO 4.1400E-04 2.4000E+Ol 2.9000E-04 9.6000E+Ol 2.2600E-04 7.2000E+02 O.OOOOE+OO Location Breathing Rate Data Time (hr) Breathing Rate (mA3

• secA-1)

O.OOOOE+OO 3.SOOOE-04 7.2000E+02 O.OOOOE+OO Location Occupancy Factor Data Time (hr) Occupancy Factor O.OOOOE+OO 1.0000E+OO 2 .4000E+Ol 6.0000E-01 9.6000E+Ol 4.0000E-01 7.2000E+02 O.OOOOE+OO USER SPECIFIED TIME STEP DATA - SUPPLEMENTAL TIME STEPS Time Time step O.OOOOE+OO l.OOOOE-01 2.0000E+OO 5.0000E-01 8.0000E+OO l.OOOOE+OO 2.4000E+Ol 2.0000E+OO 9.6000E+01 8.0000E+OO 7.2000E+02 O.OOOOE+OO

CALCULATION NO. PM-1168 REV.No. 0 PAGE NO. 35 of: 67 RADTRAD Version 3.03 (Spring 2001) run on 5/21/2014 at 18:11:52 Dose Output Exclusion Area Boundary Doses:

Time {h) = 0.0036 Whole Body Thyroid TEDE Delta dose (rem} 5.2448E-04 4.3935E-02 2.4215E-03 Accumulated dose (rem) 5.2448E-04 4.3935E-02 2.4215E-03 Low Population Zone Doses:

Time (h) = 0.0036 Whole Body Thyroid TEDE Delta dose (rem) 7.9450E-OS 6.6553E-03 3.6681E-04 Accumulated dose (rem} 7.9450E-05 6.6553E-03 3.6681E-04 Control Room Doses:

Time (h} = 0.0036 Whole Body Thyroid TEDE Delta dose (rem) 3.4386E-07 5.6989E-04 2.4950E-05 Accumulated dose (rem) 3.4386E-07 5.6989E-04 2.4950E-05 Exclusion Area Boundary Doses:

Time (h) = 1.0000 Whole Body Thyroid TEDE Delta dose (rem} 5.8398E-02 5.2144E+OO 2.8379E-01 Accumulated dose (rem) 5.8922E-02 5.2584E+OO 2.8621E-Ol Low Population Zone Doses:

Time (h) = 1.0000 Whole Body Thyroid TEDE Delta dose {rem) 8.8462E-03 7.8989E-01 4.2988E-02 Accumulated dose (rem) 8.9257E-03 7.9655E-01 4.3355E-02 Control Room Doses:

Time (h) = 1.0000 Whole Body Thyroid TEDE Delta dose (rem) 3.4917E-03 6.5060E+OO 2.8488E-Ol Accumulated dose (rem) 3.4921E-03 6.5066E+OO 2.8490E-01

CALCULATION NO. PM-1168 REV.No. 0 PAGE NO. 36 of. 67 Exclusion Area Boundary Doses:

Time (h) = 2.0000 Whole Body Thyroid TEDE Delta dose (rem) O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Accumulated dose (rem) 5.8922E-02 5.2584E+OO 2.8621E-01 Low Population Zone Doses:

Time (h) = 2.0000 Whole Body Thyroid TEDE Delta dose (rem) O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Accumulated dose (rem) 8.9257E-03 7.9655E-01 4.3355E-02 Control Room Doses:

Time (h) = 2.0000 Whole Body Thyroid TEDE Delta dose (rem) 4.3839E-05 1.1695E-01 5.1026E-03 Accumulated dose (rem) 3.5359E-03 6.6235E+OO 2.9001E-01 Exclusion Area Boundary Doses:

Time (h) = 8.0000 Whole Body Thyroid TEDE Delta dose (rem) O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Accumulated dose (rem) 5.8922E-02 5.2584E+OO 2.8621E-01 Low Population Zone Doses:

Time (h) = 8.0000 Whole Body Thyroid TEDE Delta dose (rem) O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Accumulated dose (rem) 8.9257E-03 7.9655E-01 4.3355E-02 Control Room Doses:

Time (h) = 8.0000 Whole Body Thyroid TEDE Delta dose (rem) 2.2820E-08 8.6624E-05 3.7693E-06 Accumulated dose (rem} 3.5359E-03 6.6236E+OO 2.9001E-01 Exclusion Area Boundary Doses:

Time (h) = 24.0000 Whole Body Thyroid TEDE Delta dose (rem) O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Accumulated dose (rem) 5.8922E-02 5.2584E+OO 2.8621E-01 Low Population Zone Doses:

Time (h) = 24.0000 Whole Body Thyroid TEDE Delta dose (rem) O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Accumulated dose (rem) 8.9257E-03 7.9655E-01 4.3355E-02 Control Room Doses:

Time (h) = 24.0000 Whole Body Thyroid TEDE Delta dose {rem) 1.5162E-27 1.4444E-23 6.3435E-25 Accumulated dose (rem) 3.5359E-03 6.6236E+OO 2.9001E-01 Exclusion Area Boundary Doses:

Time (h) = 96.0000 Whole Body Thyroid TEDE Delta dose (rem) O.OOOOE+OO O.OOOOE+OO 0.0000E+OO

CALCULATION NO. PM-1168 REV. No. 0 PAGE NO. 37 of; 67 Accumulated dose (rem) 5.8922E-02 5.2584E+OO 2.8621E-01 Low Population Zone Doses:

Time (h) = 96.0000 Whole Body Thyroid TEDE Delta dose (rem) O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Accumulated dose (rem) 8.9257E-03 7.9655E-01 4.3355E-02 Control Room Doses:

Time (h) = 96.0000 Whole Body Thyroid TEDE Delta dose (rem) 1.3348E-77 2.6612E-73 1.2149E-74 Accumulated dose (rem) 3.5359E-03 6.6236E+OO 2.9001E-01 Exclusion Area Boundary Doses:

Time (h) = 720.0000 Whole Body Thyroid TEDE Delta dose (rem) O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Accumulated dose (rem) 5.8922E-02 5.2584E+OO 2.8621E-Ol Low Population Zone Doses:

Time (h) = 720.0000 Whole Body Thyroid TEDE Delta dose (rem) O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Accumulated dose (rem) 8.9257E-03 7.9655E-01 4.3355E-02 Control Room Doses:

Time (h) = 720.0000 Whole Body Thyroid TEDE Delta dose (rem) 4.9505-303 1.4055-298 7.3542-300 Accumulated dose (rem) 3.5359E-03 6.6236E+OO 2.9001E-Ol 838 I-131 Summary RCS Sample Environment Control Room Time (hr) I-131 (Curies) I-131 (Curies) I-131 (Curies) 0.000 1.6738E+OO 2.1431E-03 2.5150E-05 0.004 l.0770E+Ol 8.9571E-02 1.0435E-03 0.400 1.7314E+OO 9.1197E+OO 2.3306E-02 0.700 4.3413E-01 l.0416E+Ol 7.5957E-03

1. 000 1.0885E-01 l.0741E+01 2.1068E-03

1. 300 1.0874E.,.01 1.0741E+Ol 2.4320E-04

1. 600 1. 0862E- 01 1.0741E+Ol 2.8074E-05 1.900 1. OBSOE-01 1.0741E+01 3.2408E-06 2.000 1. 0846E- 01 1. 0741E+Ol 1.5780E-06 2.300 1.0835E-01 1. 0741E+Ol l.8216E-07 2.600 1.0823E-01 1.0741E+Ol 2.1027E-08 2.900 1. OBllE-01 1. 0741E+Ol 2.4273E-09 3.200 1.0BOOE-01 1.0741E+01 2.8020E-10 3.500 1.0788E-01 1.0741E+01 3.2346E-ll 3.800 1.0776E-01 1.0741E+Ol 3.7339E-12 4.100 1. 0765E-01 1.0741E+Ol 4.3103E-13 4.400 1.0753E-01 1.0741E+Ol 4.9757E-14 4.700 l.0742E-01 1.0741E+Ol 5.7438E-15

[.__ . --*~AL~*~;LATl-~~N ~0-.-;>M-~~-;-*=i------R-EV:* No. 0 -**--*- t P~;~ N~~*;8 of 67 J

5.000 1.0730E-01 1. 074 lE+Ol 6.6304E-16 5.300 l.0719E-01 1.0741E+Ol 7.6539E-17 5.600 l.0707E-01 l.0741E+Ol 8.8354E-18 5.900 1.0695E-01 1.0741E+Ol l.0199E-18

6. 200 1.0684E-01 1.0741E+Ol 1.1774E-19 6.500 1. 0672E-01 1. 0741E-t*Ol l.3591E-20 6.800 1.0661E-01 l.0741E+Ol l.5689E-21 7.100 l.0649E-01 l.0741E+01 1. 8111E-22 7.400 1. 063 BE- 01 l.0741E+Ol 2.0907E-23 7.700 l.0627E-01 1. 074 lE+Ol 2.4134E-24 8.000 1.0615E-Ol 1.0741.E+Ol 2.7860E-25 8.300 1.0604E-01 l.0741E+Ol 3.2161E-26 8.600 1.D592E-01 1.0741E+Ol 3. 7125E-*2 7 8.900 l.0581E-01 1.0741.E+Ol 4.2856E-28 9.200 1.0569E-Ol 1 . 0741.E+Ol 4.9472E-29 9.500 1.0558E-01 l.0741E+Ol 5.7109E-30 9.800 l . 0547E-01 1.0741E+Ol 6.5925E-31 10.100 1.0535E-01 l.0741E+Ol 7. 6101E-32 10.400 l.0524E-01 1.0741E+Ol 8.7849E-33 24.000 1.0022E-01 1.0741E+Ol 2.7275E-75

96. 000 7. 7382E** 02 1.0741E+Ol 2.4687-300 720.000 8.2254E-03 1.0741E+Ol O.OOOOE+OO Cumulative Dose Summary Exclusion Area Bounda Low Population Zone Control Room Time Thyroid TEDE TEDE Thyroid TEDE (hr) (rem) (rem) (rem) (rem) (rem) (rem) 0.000 0.0000E+OO O.OOOOE+OO 0.0000E+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO 0.004 4.3935E-02 2 .4215E-03 6.6553E-03 3. 6681E-04 5.6989E-04 2.4950E-05 0 .400 4.4687E+OO 2.4451E-01 6.7693E-01 3.7038E-02 4.3262E+OO 1.8950E-01 0.700 5.1006E+OO 2.7803E-01 7.7264E-01 4.2117E-02 6.0017E+OO 2.6284E-01 1.000 5.2584E+OO 2.8621E-01 7.9655E-01 4.3355E-02 6.5066E+OO 2.8490E-01 1.300 5.2584E+OO 2.8621E-01 7.9655E-01 4.3355E-02 6.6101E+OO 2.8942E-01 1.600 5.2584E+OO 2.8621E-01 7.9655E-01 4.3355E-02 6.6221E+OO 2.8994E-01 1.900 5.2584E+OO 2.8621E-01 7.9655E-Ol 4.3355E-02 6.6234E+OO 2.9000E-01 2.000 5.2584E+OO 2.8621E-01 7.9655E-Ol 4.3355E-02 6.6235E+OO 2.9001E-01 2.300 5.2584E+OO 2.8621E-01 7.9655E-01 4.3355E-02 6.6236E+OO 2.9001E-01 2.600 5.2584E+OO 2.8621E-01 7.9655E-01 4.3355E-02 6.6236E+OO 2.9001E-01 2.900 5.2584E+OO 2.8621E-01 7. 9655E-Ol 4.3355E-02 6.6236E+OO 2.9001E-01 3.200 5.2584E+OO 2.8621E-01 7. 9655E-01 4.3355E-02 6.6236E+OO 2.9001E-01 3.500 5.2584E+OO 2.8621E-01 7. 9655E-01 4.3355E-02 6.6236E+OO 2.9001E-Ol 3.800 5.2584E+OO 2.8621E-01 7. 9655E-01 4.3355E-02 6.6236E+OO 2.9001E-01 4.100 5.2584E+OO 2.8621E-01 7.9655E-01 4.3355E-02 6.6236E+OO 2.9001E-01 4.400 5.2584E+OO 2.8621E-01 7.9655E-01 4.3355E-02 6.6236E+OO 2.9001E-01 4.700 5.2584E+OO 2.8621E-01 7. 9655E-01 4.3355E-02 6.6236E+OO 2.9001E-01 5.000 5.2584E+OO 2.8621E-01 7. 9655E-01 4.3355E-02 6.6236E+OO 2.9001E-01 5.300 5.2584E+OO 2.8621E-01 7.9655E-01 4.3355E-02 6.6236E+OO 2.9001E-01 5.600 5.2584E+OO 2.8621E-01 7.9655E-01 4.3355E-02 6.6236E+OO 2.9001E-01 5.900 5.2584E+OO 2.8621E-01 7.9655E-01 4.3355E-02 6.6236E+OO 2.9001E-01 6.200 5.2584E+OO 2.8621E-01 7.9655E-01 4.3355E-02 6.6236E+OO 2.9001E-01 6.500 5.2584E+OO 2.8621E-01 7.9655E-01 4.3355E-02 6.6236E+OO 2.9001E-01 6.800 5.2584E+OO 2.8621E-01 7.9655E-01 4.3355E-02 6.6236E+OO 2.9001E-01 7.100 5.2584E+OO 2.8621E-01 7. 9655E- 01 4.3355E-02 6.6236E+OO 2.9001E-01 7.400 5.2584E+OO 2.8621E-01 7.9655E-01 4.3355E-02 6.6236E+OO 2.9001E-01 7.700 5.2584E+OO 2.8621E-01 7.9655E-01 4.3355E-02 6.6236E+OO 2. 9001E- 01

CALCULATION NO. PM-1168 REV.No. 0 PAGE NO. 39 of; 67 8.000 5.2584E+OO 2.8621E-Ol 7. 9655E-01 4.3355E-02 6.6236E+OO 2.9001E-01 8.300 5.2584E+OO 2.8621E-01 7.9655E-01 4.3355E-02 6.6236E+OO 2.9001E-01 8.600 5.2584E+OO 2.8621E-01 7.9655E-01 4.3355E-02 6.6236E+OO 2.9001E-01 8.900 5.2584E+OO 2.8621E-01 7.9655E-Ol 4.3355E-02 6.6236E+OO 2.9001E-01 9.200 S.2584E+OO 2.8621E-Ol 7.965SE-Ol 4.3355E-02 6. 6236E+'OO 2.9001E-01 9.500 S.2584E+OO 2.8621E-01 7.9655E-Ol 4.3355E-02 6.6236E+OO 2.9001E-01 9.800 5.2584E+OO 2.8621E-01 7.9655E-Ol 4.3355E-02 6.6236E+OO 2.9001E-01 10.100 5.2584E+OO 2.8621E-01 7.9655E-01 4.3355E-02 6.6236E+OO 2.9001E-01 10.400 5.2.584E+OO 2 .. 8621E-01 7.9655E.:.Ol 4.335SE-02 6.6236E+OO 2.9001E-Ol 24.000 5.2584E+OO 2.8621E-01 7.9655E-Ol 4.3355E-02 6.6236E+OO 2.9001E-01 96.000 5.2584E+OO 2.8621E-Ol 7.9655E-01 4.335SE-02 6.6236E+OO 2.9001E-01 720.000 S.2584E+OO 2.8621E-01 7.9655E-01 4.3355E-02 6.6236E+OO 2.9001E-01 Worst Two-Hour Doses Exclusion Area Boundary Time Whole Body Thyroid TEDE (hr) (rem) (rem) (rem) 0.0 5.8922E-02 5.2584E+OO 2.8621E-01

CALCULATION NO. PM-1168 REV.No. 0 PAGE NO. 40 of.

• 67 Attachment 13.2 MicroShield Output File: PBRWSAMP.MS5 MicroShield v5.05 (5.05-00238)

PSEG Nuclear LLC Page 1 File Ref:

DOS File: PBRWSAMP.MS5 Date:

Run Date: April 10, 2014 By:

Run Time: 2:29:15 PM Checked:

Duration: 00:00:17 case

Title:

Case l Description1 PB 3/4" RW Sample Line Dose Rates - CRDA Geometry: 7 - Cylinder Volume - Side Shields Source Dimensions Height 609.6 cm 20 ft 0.0 in Radius 0.942 cm 0.4 in Dose Points

1. 1 x

31.8135 cm x.

304.8 cm

.z.

O cm 1 ft 0.5 in 10 f t o.o in o. o in

1. 2 62.2935 cm 304.8 cm o cm

... # 3 2 ft o. 5 92.7735 in cm 10 ft o. o in 304.8 cm 0.0 in o cm 3 ft 0.5 in 10 ft 0.0 in o.o in

1. 4 153.7335 cm 304.8 cm 0 cm 5 ft 0.5 in 10 ft 0.0 in O. 0 in Shields Shield Name Dimension Material Density Source 103.779 in 3 Water 0.754 Transition Air 0.00122 Air Gap Air 0. 00122 Wall Clad .154 in Iron 7. 87 Source Input Grouping Method : Standard Indices Number of Groups : 25 Lower Energy Cutoff : 0.015 Photons < 0.015 : Excluded Library : Grove Nuclide curies becguerels uCi/cm* Bg/cm 3 Cs-134 4.0920e-001 1. 5140e+010 2. 4062e+002 8.9028e+006 Cs-136 1.1580e-001 4 .2846e+009 6. 8092e+001 2.5194e+006 Cs-137 2.4660e-001 9 .1242e+009 1. 4501e+002 5.3652e+006 Cs-138 3.1560e+OOO l .1677e+Oll 1. 8558e+003 6.8664e+007 I-131 1.5360e+OOO 5.6832e+010 9.0319e+002 3.3418e+007 I-132 2.2160e+OOO 8 .1992e+Ol0 1. 3030e+003 4.8213e+007 I-133 3.1610e+OOO 1.1696e+Oll 1. 8587e+003 6.8773e+007 I-134 3.SlOOe+OOO 1. 2987e+Oll 2. 0639e+003 7.6366e+007 I-135 2.9530e+OOO 1. 0926e+Oll 1. 7364e+003 6.4247e+007 Kr-83m 2.6420e-001 9. 7754e+009 1. 5535e+002 5.7481e+006 Kr-85 2.SllOe-002 9.2907e+008 1.4765e+001 5.4631e+005 Kr-85m 5.8730e-001 2. l 730e+Ol0 3 .4534e+002 1.2778e+007 Kr-87 1.1570e+OOO 4 .2809e+Ol0 6. 8034e+002 2.5172e+007 Kr-88 1.6330e+OOO 6. 042le+010 9. 6023e+002 3.5529e+007 Rb-86 3.8770e-003 l .4345e+008 2 .2797e+OOO 8.4350e+004 Rb-88 1.4420e+OOO 5. 3354e+010 8 .4792e+002 3.1373e+007 Xe-13lm 2.0760e-002 7. 6812e+008 1. 2207e+001 4.5167e+005 Xe-133 3.7670e+OOO l.3938e+Oll 2 .2151e+003 8.1957e+007 Xe-133m i.1770e-001 4. 3549e+009 6. 9210e+001 2.5608e+006 Xe-135 1.4690e+OOO 5. 4353e+010 8. 6380e+002 3.1960e+007 Xe-135m 7.4210e-001 2. 7458e+010 4. 3637e+002 1.6146e+007 Xe-138 3.3050e+OOO 1.2229e+Oll l.9434e+003 7.1906e+007 Buildup

CALCULATION NO. PM-1168 REV.No. 0 PAGE NO. 41 of* 67 Page 2 DOS File: PBRWSAMP.MS5 Run Date: April 10, 2014 Run Time: 2:29:15 PM Duration: 00:00:17 The material reference is : Source Integration Parameters Radial 15 Circumferential 15 Y Direction (axial) 15 Results - Dose Point # l - (12.525,120,0) in Energy Activity Flueuce Rate Fluence Rate Exposure Rate Exposure Rate

~ photons/sec MeV/cm 2 /sec Mev/cm 2 /sec m&L1:u: m&L1:u:

No Buildup With Buildup No j3uildup With Buildup 0.03 8.956e+10 4. 649e-08 1. 006e-06 4. 607e-10 9. 971e-09 0.04 3.907e+08 4.707e-04 l.975e-02 2.082e-06 8.737e-05 0.06 S.340e+08 2.815e+OO 1.0lle+02 5.59le-03 2.009e-Ol 0.08 5.291e+l0 3.354e+03 5.574e+04 5.308e+OO 8.82le+01 0.1 2.881e+08 5.395e+Ol 4.768e+02 8.253e-02 7.295e-01 0.15 3.447e+l0 1. 987e+04 7. 987e+04 3 .272e+Ol 1. 315e+02 0.2 7.931e+l0 7.617e+04 2.203e+05 1.344e+02 3.888e+02 0.3 S.653e+10 9.693e+04 2.060e+05 1.839e+02 3.907e+02 0.4 1. 363e+ll 3.394e+05 6.268e+05 6.613e+02 l.221e+03 0.5 2 .216e+ll 7.301e+05 l.232e+06 l.433e+03 2.417e+03 0.6 1. 772e+ll 7. 3lle+OS l.160e+06 l.427e+03 2.263e+03 0.8 3. 713e+ll 2 .176e+06 3 .166e+06 4 .138e+03 6.023e+03

1. 0 1. 782e+ll 1.367e+06 l.890e+06 2.520e+03 3.484e+03 1.5 2.014e+ll 2. 4 99e+06 3 .183e+06 4. 2 04e+03 5.356e+03 2.0 1.442e+ll 2. 495e+06 3. 048e+06 3. 857e+03 4.714e+03 3.0 1.774e+l0 4. B30e+05 5. 644e+05 6. 553e+02 7.657e+02 5.0 7.650e+07 3.610e+03 4.044e+03 4.139e+OO 4.635e+OO TOTALS: 1.762e+12 1.102e+07 1.544e+07 l.926e+04 2.725e+04 Energy Results - Dose Point # 2 Activit:i:::

- ( 2 4

• 52 5 t 12 0 I 0) in FluenQe Rate FluenQe E,a!;;e Exposure Rate Exposure Re,te MeV :ghoj;onsl..§lec MeV Lcm 2 1..§ec MeVLcm 2 L!ieC m&L1:u: m&L1:u:

No 13yiJ.du12 With BuiJ.gua No Builgu12 Ni th Buildu12 0.03 8.956e+10 1.897e-OB 4.098e-07 1.BBOe-10 4.061e-09 0.04 3.907e+08 2.146e-04 9.230e-03 9.491e-07 4.082e-05 0.06 5.340e+08 1.442e+OO 5.198e+Ol 2.864e-03 l.032e-Ol 0.08 5.291e+l0 1.715e+03 2.846e+04 2. 713e+OO 4.503e+Ol 0.1 2.881e+OB 2.750e+Ol 2.427e+02 4.207e-02 3. 714e-Ol 0.15 3.447e+10 1.009e+04 3.996e+04 1.662e+Ol 6.580e+Ol 0.2 7.93le+10 3.859e+04 1.090e+05 6.810e+Ol l.924e+02 0.3 5.653e+l0 4.895e+04 1. 013e+05 9.285e+Ol l.921e+02 0.4 l.363e+ll 1.710e+05 3.075e+05 3.332e+02 5.992e+02 0.5 2.216e+ll 3. 672e+05 6.037e+05 7.208e+02 1.185e+03 0.6 l.772e+ll 3.672e+05 5.682e+05 7.167e+02 1.109e+03 0.8 3.713e+ll l.090e+06 l.550e+06 2.073e+03 2. 948e+03

1. 0 1.782e+ll 6.83le+05 9.245e+05 l.259e+03 l.704e+03 1.5 2. 014e+ll 1.243e+06 1.554e+06 2.092e+03 2.615e+03 2.0 1.442e+ll l.237e+06 1.487e+06 1.913e+03 2.299e+03 3.0 1. 774e+l0 2.386e+05 2.749e+05 3.238e+02 3.730e+02 5.0 7.650e+07 1.778e+03 l.969e+03 2.038e+OO 2.258e+OO TOTALS: 1.762e+l2 5.499e+06 7.55le+06 9.614e+03 1. 333e+04 Results - Dose Point # 3 - (36.525,120,0) in Energy Activity Fluence Rate Fluence Rate Exposure Rate Exposure*Rate MeV photons/sec MeV /cm 2 !..sec MeV(cm 2 Lsec m&L1:u: m&L1:u:

No Buildup With Buildup No Byildup With Buildup 0.03 8.956e+10 1.259e-08 2.73Se-07 1.248e-10 2.71le-09

CALCULATION NO. PM-1168 REV.No. 0 PAGE NO. 42of1 67 Page  : 3 DOS File: PBRWSAMP.MSS Run Date: April 10, 2014 Run Time: 2:29:15 PM Duration: 00:00:17 Energv: Actiyit~ Fluence Rat;e Fluence Rate Expgsure Rat;e Expgsure Rate MeV photons/sec MeY/cm 2 /sec MeV/cm 2 /sec mEL..h.r. mRLlll:

No Buildup With Buildup No Buildup With Buildu,p 0.04 3.907e+08 l.450e-04 6.218e-03 6.412e-07 2.750e-05 0.06 5.340e+08 9.608e-01 3.472e+Ol 1. 908e- 03 6.897e-02 0.08 5.29le+l0 l.142e+03 l.898e+04 1.808e+OO 3.004e+01 0.1 2.88le+08 1. 829e+Ol 1.598e+02 2.798e-02 2.445e-01 0.15 3.447e+l0 6.658e+03 2.556e+04 l.096e+Ol 4.209e+Ol 0.2 7.931e+10 2.533e+04 6.902e+04 4.470e+Ol 1.218e+02 0.3 5.653e+10 3.195e+04 6 .401e+04 6.061e+Ol 1.214e+02 0.4 l. 363e+ll 1.ll3e+OS 1.944e+05 2.169e+02 3.788e+02 0.5 2.216e+ll 2.384e+OS 3.818e+OS 4.680e+02 7.494e+02 0.6 1. 772e+ll 2.380e+OS 3.594e+05 4.645e+02 7.014e+02 0.8 3.713e+ll 7.043e+OS 9.807e+05 1.340e+03 l.865e+03

1. 0 1. 782e+ll 4.405e+05 5.849e+05 8.119e+02 l.078e+03 1.5 2. Ol4e+ll 7.983e+OS 9.829e+OS 1. 343e+03 1. 654e+03 2.0 l.442e+11 7.924e+05 9.397e+05 1.225e+03 1.453e+03 3.0 1.774e+10 l.524e+05 l.737e+OS 2.067e+02 2.357e+02 5.0 7.650e+07 1.133e+03 1.244e+03 1. 298e+OO 1. 427e+OO TOTALS: 1.762e+12 3.542e+06 4.776e+06 6.195e+03 8.433e+03 Results - Dose Point # 4 - (60.525,120,0) in Energy Activity Fluence Rate Fluence Rate Exposure Rate Exposure Rate

~ phgt;gns/sec MeV /cm2 /sec MeV /cm 2 /sec mEL..h.r. mR/hr No Buildup With Buildui;i No Buildup With Buildup 0.03 8.956e+10 7.513e-09 l.630e-07 7 .446e-ll 1.616e-09 0.04 3.907e+08 8.580e-OS 3.687e-03 3.795e-07 l.63le-05 0.06 S.340e+08 5.709e-01 2.069e+Ol l.134e-03 4. llOe-02 0.08 5.29le+l0 6.732e+02 1.098e+04 l.065e+OO l.737e+Ol 0.1 2.881e+08 1.062e+Ol 8.836e+01 l.624e-02 l.352e-Ol 0.15 3.447e+10 3.76le+03 1.353e+04 6.194e+OO 2.229e+Ol 0.2 7.931e+10 1.413e+04 3.610e+04 2.495e+01 6.37le+Ol 0.3 5.653e+l0 l.765e+04 3.362e+04 3.347e+Ol 6.378e+Ol 0.4 1.363e+ll 6 .113e+04 1.023e+OS l.19le+02 l.993e+02 0.5 2.216e+ll 1. 305e+05 2.012e+OS 2.56le+02 3.949e+02 0.6 1.772e+ll 1. 298e+OS 1. 895e+OS 2.534e+02 3.700e+02 0.8 3.713e+ll 3.826e+OS 5.178e+05 7.277e+02 9.849e+02

1. 0 l.782e+ll 2.385e+OS 3.088e+OS 4.396e+02 5.693e+02 1.5 2. 014e+11 4.298e+OS 5.190e+OS 7.23le+02 8.732e+02 2.0 1.442e+ll 4.252e+OS 4.961e+OS 6.575e+02 7.67le+02 3.0 1.774e+10 8.147e+04 9.167e+04 l.105e+02 l.244e+02 5.0 7.650e+07 6.037e+02 6.570e+02 6.921e-Ol 7.532e-Ol TOTALS: 1.762e+12 1.916e+06 2.521e+06 3.353e+03 4.45le+03

Attachment 13.3 RAD'fRAD Nuclide Inventory F'ile: PHCRDASMPOO__ def.b:t Nuclide Inventory Name: Post-CRDA RW Sample Line Activity Normalized MACCS Sample 4030 MWt BWR Core Inventory Power Level:

O.lOOOE+Ol Nuclides:

60 Nuclide 001:

Co-58 7

0. 611 712 OOOOE+07 0.5800E+02 O.OOOOE+OO none 0.0000E+OO none O.OOOOE+OO none O.OOOOE+OO Nuclide 002:

Co-60 7

0 .1663401096E+09 0.6000E+02 0.0000E+OO none O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO Nuclide 003:

Kr-83m 1

0.6588000000E+04 0.8300E+02 0.4667E+Ol none O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO Nuclide 004:

Kr-85 1

0.3382974720E+09 0.8500E+02 0.4436E+OO none 0.0000E+OO none 0.0000E+OO none O.OOOOE+OO Nuclide 005:

Kr-85m 1

0.1612800000E+05 0.8500E+02 0.1038E+02 Kr-85 0.2100E+OO none 0.0000E+OO none O.OOOOE+OO Nuclide 006:

Kr-87

[ --C-'A_I_,,_c_'_t_J_~~-A-_.-r_1_c_;_N_N_f_>._P_M_-_1_16_8_ _ __..___,_~*****-~~~~. ~~!i-**-----I~**~:;;;;-~~~~-:r, 67 1

0.4578000000E+04 0.8700E+02 0.2045E+02 Rb-87 O.lOOOE+Ol none O.OOOOE+OO none O.OOOOE+OO Nuclide 007:

Kr-88 1

0.1022400000E+05 0.8800E+02 0.2885E+02 Rb-88 O.lOOOE+Ol none O.OOOOE+OO none O.OOOOE+OO Nuclide 008:

Rb-86 3

0.1612224000E+07 0.8600E+02 0.2739E-Ol none O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO Nuclide 009:

Rb-88 3

0 . 1068000000E+04 0 . 8800E+02 0.1019E+02 none O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO Nuclide 010:

Sr-90 5

0.9189573120E+09 0.9000E+02 O.OOOOE+OO Y-90 O . lOOOE+Ol none O.OOOOE+OO none O.OOOOE+OO Nuclide 011:

Sr-91 5

0.3420000000E+05 0.9100E+02 O.OOOOE+OO Y-91m 0.5800E+OO Y-91 0.4200E+OO none O.OOOOE+OO Nuclide 012:

Sr-92 5

0.9756000000E+04 0.9200E+02 O.OOOOE+OO

Y-92 O.lOOOE+Ol none O.OOOOE+OO none O.OOOOE+OO Nuclide o13:

Y-90 9

0.2304000000E+06 0.9000E+02 O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO Nuclide 014:

Y-91 9

0.5055264000E+07 0.9100E+02 O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO Nuclide 015:

Y-92 9

0.1274400000E+05 0.9200E+02 O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO Nuclide 016:

Y-93 9

0.3636000000E+05 0.9300E+02 O.OOOOE+OO Zr-93 O.lOOOE+Ol none O.OOOOE+OO none O.OOOOE+OO Nuclide 017:

Zr-95 9

0.5527872000E+07 0.9500E+02 O.OOOOE+OO Nb-95m 0.7000E-02 Nb-95 0.9900E+OO none 0.0000E+OO Nuclide 018:

Zr-97 9

0.6084000000E+05 0.9700E+02 O.OOOOE+OO Nb-97m 0.9500E+OO Nb-97 0.5300E-01 none O.OOOOE+OO Nuclide 019:

CALCULATION NO. PM-1168 REV.No. 0 PAGE NO. 46 of' 67 Nb-95 9

0.3036960000E+07 0.9500E+02 O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO Nuclide 020:

Mo-99 7

0.2376000000E+06 0.9900E+02 O.OOOOE+OO Tc-99rn 0.8800E+OO Tc-99 0.1200E+OO none O.OOOOE+OO Nuclide 021:

Tc-99rn 7

0.2167200000E+05 0.9900E+02 O.OOOOE+OO Tc-99 O.lOOOE+Ol none O.OOOOE+OO none O.OOOOE+OO Nuclide 022:

Ru-103 7

0.3393792000E+07 0.1030E+03 O.OOOOE+OO Rh-103rn O.lOOOE+Ol none O.OOOOE+OO none O.OOOOE+OO Nuclide 023:

Ru-105 7

0.1598400000E+05 0.1050E+03 O.OOOOE+OO Rh-105 O.lOOOE+Ol none O.OOOOE+OO none O.OOOOE+OO Nuclide 024:

Ru-106 7

0.3181248000E+OB 0.1060E+03 O.OOOOE+OO Rh-106 O.lOOOE+Ol none O.OOOOE+OO none O.OOOOE+OO Nuclide 025:

Rh-105 7

0.1272960000E+06 0.1050E+03

CALCULATION NO. PM-1168 REV.No. 0 PAGE NO. 47 of* 67 O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO Nuclide 026:

Sb-127 4

0.3326400000E+06 0.1270E+03 O.OOOOE+OO Te-127m 0.1800E+OO Te-127 0.8200E+OO none O.OOOOE+OO Nuclide 027:

Sb-129 4

0.1555200000E+05 0.1290E+03 O.OOOOE+OO Te-129m 0.2200E+OO Te-129 0.7700E+OO none O.OOOOE+OO Nuclide 028:

Te-127 4

0.3366000000E+05 0.1270E+03 0.0000E+OO none O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO Nuclide 029:

Te-127m 4

0.9417600000E+07 0.1270E+03 O.OOOOE+OO Te-127 0.9800E+OO none O.OOOOE+OO none O.OOOOE+OO Nuclide 030:

Te-129 4

0.4176000000E+04 0.1290E+03 O.OOOOE+OO I-129 O.lOOOE+Ol none O.OOOOE+OO none O.OOOOE+OO Nuclide 031:

Te-129m 4

0.2903040000E+07 0.1290E+03 O.OOOOE+OO Te-129 0.6500E+OO I-129 0.3500E+OO none O.OOOOE+OO

CALCOLA TION NO. PM-1168 -~ I *=--~~---******_;_E_~_~**N_***_o._(_)_ _ _ __,_____P_A_G_E_*~-?:*_4~~->~:~,. . _6_;]

Nuclide 032:

Te-131m 4

0.1080000000E+06

0. l310E+03 O.OOOOE+OO Te-131 0.2200E+OO I-131 0.7800E+OO none 0.0000E+OO Nuclide 033:

Te-132 4

0.2815200000E+06 0.1320E+03 0.000DE+OD I-132 O.lOOOE+Ol none O.OOOOE+OO none O.OOOOE+OO Nuclide 034:

r-131 2

0.6946560000E+06 0.1310E+03 0.1086E+02 Xe-131m O.llOOE-01 none O.OOOOE+OO none O.OOOOE+OO Nuclide 035:

I-132 2

0.8280000000E+04 0.1320E+03 0.1566E+02 none O.OOOOE+OO none 0.0000E+OO none O.OOOOE+OO Nuclide 036:

I-133 2

0.7488000000E+05 0 .1330E+03 0.2234E+02 Xe-133m 0.2900E-Ol Xe-133 0.9700E+OO none O.OOOOE+OO Nuclide 037:

I-134 2

0.3156000000E+04

0. 1340E+03 0.2481E+02 none 0.0000E+OO none 0.0000E+OO none O.OOOOE+OO Nuclide 038:

I-135 2

0.2379600000E+05

CALCULATION NO. PM-1168 REV. No. O PAGE NO. 49 of* 1 67 0.1350E+03 0.2087E+02 Xe-135m 0.1500E+OO Xe-135 0.8500E+OO none O.OOOOE+OO Nuclide 039:

Xe-131m 1

0.1028160000E+07 0 .1310E+03 0.3367E+OO none O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO Nuclide 040:

Xe-133 1

0.4531680000E+06 0.1330E+03 0.6656E+02 none O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO Nuclide 041:

Xe-133m 1

0.1890432000E+06 0.1330E+03 0.2079E+Ol Xe-133 O.lOOOE+Ol none O.OOOOE+OO none O.OOOOE+OO Nuclide 042:

Xe-135 1

0.3272400000E+05 0.1350E+03 0.2595E+02 Cs-135 O.lOOOE+Ol none O.OOOOE+OO none O.OOOOE+OO Nuclide 043:

Xe-135rn

.1 0.9174000000E+03 0 .1350E+03 0 .1311E+02 Xe-135 O.lOOOE+Ol none O.OOOOE+OO none O.OOOOE+OO Nuclide 044:

Xe-138 1

0.8502000000E+03 0.1380E+03 0.5839E+02 Cs-138 O.lOOOE+Ol none O.OOOOE+OO

none O.OOOOE+OO Nuclide 045:

Cs-134 3

0.6507177120E+08 0 .1340E+03 0.2891E+Ol none O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO Nuclide 046:

Cs-136 3

0.1131840000E+07 0 .1360E+03 0.8181E+OO none O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO Nuclide 047:

Cs-137 3

0.9467280000E+09 0.1370E+03 0.1743E+Ol Ba-137m 0.9500E+OO none O.OOOOE+OO none O.OOOOE+OO Nuclide 048:

Cs-138 3

0.1932000000E+04 0 .1380E+03 0.2230E+02 none 0.0000E+OO none O.OOOOE+OO none 0.0000E+OO Nuclide 049:

Ba-140 6

0.1100736000E+07 0.1400E+03 O.OOOOE+OO La-140 O.lOOOE+Ol none O.OOOOE+OO none O.OOOOE+OO Nuclide 050:

La-140 9

0.1449792000E+06 0.1400E+03 O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO none 0.0000E+OO Nuclide 051:

La-141 9

0.1414800000E+05 0.1410E+03 O.OOOOE+OO Ce-141 O.lOOOE+Ol none O.OOOOE+OO none O.OOOOE+OO Nuclide 052:

La-142 9

0.5550000000E+04 0.1420E+03 O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO Nuclide 053:

Ce-141 8

0.2808086400E+07 0.1410E+03 O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO Nuclide 054:

Ce-143 8

0.1188000000E+06 0.1430E+03 0.0000E+OO Pr-143 O.lOOOE+Ol none O.OOOOE+OO none O.OOOOE+OO Nuclide 055:

Ce-144 8

0.2456352000E+08 0.1440E+03 0.0000E+OO Pr-144m 0.lBOOE-01 Pr-144 0.9800E+OO none O.OOOOE+OO Nuclide 056:

Pr-143 9

0.1171584000E+07 0.1430E+03 0.0000E+OO none O.OOOOE+OO none O.OOOOE+OO none O.OOOOE+OO Nuclide 057:

Nd-147 9

0.9486720000E+06 0.1470E+03 0.0000E+OO Pm-147 O.lOOOE+Ol

CALCULATION NO. PM-1168 REV.No. 0 PAGE NO. 52 of. 67 none O.OOOOE+OO none O.OOOOE+OO Nuclide 058:

Np-239 8

0.2034720000E+06 0.2390E+03 O.OOOOE+OO Pu-239 O.lOOOE+Ol none O.OOOOE+OO none O.OOOOE+OO Nuclide 059:

Pu-241 8

0.4544294400E+09 0.2410E+03 O.OOOOE+OO U-237 0.2400E-04 Am-241 O.lOOOE+Ol none O.OOOOE+OO Nuclide 060:

Cm-242 9

0.1406592000E+08 0.2420E+03 O.OOOOE+OO Pu-238 O.lOOOE+Ol none O.OOOOE+OO none O.OOOOE+OO End of Nuclear Inventory File

CALCULATION NO. PM*H68 REV. No. 0 PAGE NO. 53 of: 67 Attachment 13.4 RA DTRAD Release I~'raction and Timing File: pbcrda_rfttxt Release Fraction and Ti.ming Name: PBAPS Control Rod Drop Accident Fission Product Gap Inventory Duration (h) : NON-LOCA Accident chk inventory 0.0036E+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Noble Gase['.3:

O.lOOOE+Ol O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Iodine:

O.lOOOE+Ol 0.0000E+OO O.OOOOE+OO O.OOOOE+OO Cesium:

0.1000£+01 O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Tellurium:

O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Strontium:

O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Barium:

O.OOOOE+OO 0.0000E+OO O.OOOOE+OO O.OOOOE+OO Ruthenium:

O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Cerium:

O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Lanthanum:

0.0000E+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Non-Radioactive Aeror;ols (kg):

O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO End of Release File

CALCULATION NO. PM-1168 REV. No. 0 r-------"--"*"1 PAGE NO. 54 of' 67 Attachment 13.5 RADTRAD Dose Conversion Factor File: pbcrda_fg11&12.txt HCGS __ FGR1l&cl2 added 7 nuclides; de1eted Sr" 89, Ba-139, Cm244 ,AM-242, Pu23B***240 2/2001 Implicit daughter halflives (m) less than 90 and less than 0.100 of parent 9 ORGANS DEFINED IN THIS FILE:

GONADS BREAST LUNGS RED MARR BONE SUR THYROID REMAINDER EFFECTIVE SKIN (FGR) 60 NUCLIDES DEFINED IN THIS FILE:

Co-58 y Co*GO y Kr-f33m data entered by Gopal J. Patel NUCORE Kr**85 Kr-85m Kr*87 Kr**88 Rb*86 D Rb-88 data entered by Gopal ,J. Patel NUCORE Sr-90 y Sr-91 y Including:Y**91m Sr-92 Y Y-90 Y Y-91 Y Y-92 Y Y-93 Y Zr-95 D Zr-97 y Incluc1ing:Nb-97m , Including:Nb-97 Nb-*95 Y Mo-99 Y Tc-99m D Ru-103 y Including:Rh-103m Ru-105 y Ru-106 y Including:Rh-106 Rh-105 y Sb-12 7 w Sb-129 W Te-127 W Te-127m W Te-129 W Te-129m w Including:Te-129 Te-Ulm w Including:Te 131 Te-132 w I-131 D I-132 D I-133 D I-134 D I-135 D :Xe**135m Xe-l31m data entered by Gopal J. Patel NUCORE Xe-133 Xe-133m data entered by Gopal J. Patel NU CORE Xe-135 Xe-135m data entered by Go pal J. Patel NUCORE/10/08/2001 Xe-138 data entered by GopaJ J. Patel NUCORE/10/08/2001 Cs-134 D Cs-136 D Cs-13 7 D :Ba-137m Cs-13 8 data entered by Go pal J. Patel NU CORE Ba-140 D

CALCULA TllON REV. No. 0 NO. 55 of.

La-140 W La-141 D r.,c:i-142 D Ce *141 Y Ce-143 Y Ce-144 y Including:Pr-144m, Including:Pr-144 Pi>l43 y Nd-*147 y Np-23 9 w Pu-241 Y Cm-242 W CLOUDSHINE GROUND GROUND GROUND INHALED INHJ'.\,LED lNCJE:STION SHINE 8HR SHINE ?DAY :JIUNE RATE ACUTE CHRONIC Co*-58 GONADS 4.660E-14 2.867E-11 5.828E-10 9.970E-16-1.000E+OO 6.l?OE-10 l.040E-09 BREAST 5.JOOE-14 2.737E-ll 5.565E-10 9.520E-16-1.000E+OO 9.370E-10 l.790E-10 LUNGS 4.640E-14 2.617E-11 5.319E-10 9.lOOE-16-l.OOOE+OO 1.600£-08 8.SJOE-11 RED MARR 4.530E-14 2.671E-ll 5.430E-10 9.290E-16-1.000E+OO 9.230E-10 2.GOOE-10 BONE SUR 7.410E-14 3.795E-11 7.716£-10 1.320E-15-1.000E+OO 6.930E-10 l.250E-10 THYROID 4.770E-l4 2.720E-ll 5.SJOE-10 9.460E-16-l.OOOE+OO 8.720E-10 6.310E-11 REMAINDER 4.440E-14 2.585E-11 5.255E-10 8.990E-16-l.OOOE+OO 1.890E-09 1.5808-09 EFFECTIVE 4.760E-14 2.732E-11 S.553E-10 9.SOOE-16-1.000E+OO 2.940E-09 8.0908-10 SKIN (FGR) 5.SBOE-14 3.278E-11 6.664£-10 1.140E-15-l.OOOE+OO O.OOOE+OO O.OOOE+OO Co-60 GONADS l.230E-13 7.056E-ll 1.4808-09 2.450E-l5-l.OOOE+OO 4.760E-09 3.190E-09 BREAST l.390E-l3 6.739E-ll l.413E-09 2.340E-15-l.OOOE+OO 1.840E-08 l.lOOE-09 LUNGS l.240E-13 6.537E-ll l.371E-09 2.270E-15-l.OOOE+OO 3.450E-07 8.770E-10 RED MARR l.230E-13 6.710E-11 1.407E-09 2.330E-15-1.000E+OO 1.720E-08 l.320E-09 BONE SUR 1.780£-13 B.956E-ll l.879E-09 3.llOE-15-1.000E+OO l.350E-08 9.390E-10 THYIWID 1.270E-13 6.480E-11 l.359E-09 2.250E-15-l.OOOE+OO l.620E-08 7.880E-10 REMA.INDER 1.200E-13 6.508E-ll 1.3658-09 2.260E-15-1.000E+OO 3.GOOE-08 4.970E-09 EFFECTIVE l.260E-13 6.768E-11 1.419£-09 2.350E-15-l.OOOE+OO 5.910E-08 2.770E-09 SKIN (FGR) l.450E-13 7.948£-11 1.667E-09 2.760E-15-1.000E+OO O.OOOE+OO O.OOOE+OO Kr- 83m GONJl.DS 1.710E-18 0.000E+OO O.OOOE+OD 0.000E+00-1.000E+OO O.OOOE+OO O.OOOE+OO BREAST 5.0SOE-18 O.OOCE+OO 0.000E+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO LUNGS l.640E-19 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO RED MARR 3.830E-19 O.OOOE+OO 0.000E+OO O.OOOE+00-1.000E+OO O.OOOE+OO 0.000E+OO BONE SUR 2.250E-l8 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO THYIWID 6.430E-l9 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO REMAINDER 5.300E-19 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO EFFECTIVE 1.SOOE-18 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO SKIN (FGR) 3.560E-17 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO Kr-85 GONADS 1.170E-16 8.121E-14 1.704E-12 2.820E-18-1.000E+OO O.OOOE+OO O.OOOE+OO BREAST l.340E-16 7.891E-14 l.656E-12 2.740E-18-1.000E+OO O.OOOE+OO O.OOOE+OO LUNGS l.140E-16 7.056£-14 1.481E-12 2.450E-l8-1.000E+OO 0.0008+00 O.OOOE+OO RED fv'iARR l.090E-16 6.998E-14 l.469E-12 2.430E-l8-l.OOOE+OO 0.000E+OO 0.0008+00 BONE SUR 2.200E-16 l.287E-13 2.702E-12 4.470E-18-l.OOOE+OO 0.000E+OO O.OOOE+OO THYROID 1.180E-16 7.459E-14 1.565E-12 2.590E-18-1.000E+OO O.OOOE+OO O.OOOE+OO REJ\l'AINDER l.090E-16 6.941E-14 1.457E-12 2.410E-l8-1.000E+OO O.OOOE+OO O.OOOE+OO EFFECTIVE l.190E-15 7.603E-14 1.596E-12 2.640E-18-l.OOOE+OO O.OOOE+OO O.OOOE+OO SKIN (FGR) 1.320E-14 2.304E-11 4.835E-10 8.000E-16-1.000E+OO O.OOOE+OO O.OOOE+OO Kr-85m GONADS 7.310E-15 2.594E-12 3.653E-12 l.570E-16-1.000E+OO O.OOOE+OO O.OOOE+OO BREAST 8.410E-l5 2.527E-12 3.560E-12 l.530E-16-l.OOOE+OO 0.0008+00 0.0008+00 LUNGS 7.040E-15 2.379E-12 3.JSlE-12 l.440E-16-1.000E+OO O.OOOE+OO O.OOOE+OO RED MARR 6.430E-15 2.345E-l2 3.304E-12 1.420E-16-l.OOOE+OO O.OOOE+OO O.OOOE+OO BONE SUR l.880E-14 5.286E-l2 7.446E-12 3.200E-16-l.OOOE+OO O.OOOE+OO O.OOOE+OO THYROID 7.330E-15 2.395E-12 3.374E-12 1.450E-16-l.OOOE+OO O.OOOE+OO O.OOOE+OO REMAINDB-:R 6.640E-15 2.313E-12 3.257E-12 l.400E-16-1.000E+OO O.OOOE+OO O.OOOE+OO EFFECTIVE 7.480E-15 2.SllE-12 3.537E-12 1.520E-16-l.OOOE+OO O.OOOE+OO O.OOOE+OO SKIN (FGR) 2.240E-14 2.247E-ll 3.164E-11 l.360E-15-1.000E+OO O.OOOE+OO 0.000E+OO Kr-87 GONADS 4.000E-14 4.962E-12 5.026E-l2 7.610E-15-l.OOOE+OO O.OOOE+DO O.OOOE+OO BREAST 4.SOOE-14 4.740E-12 4.802E-12 7.2708-16-1.0DDE+OO O.ODOE+OO O.OOOE+OO LUNGS 4.040E-14 4.603E-12 4.663E-12 7.060E-15-1.000E+OO O.ODOE+DO O.OOOE+OO

CALCtJLAT10N NO. PM-U.68 REV. NO. 56 of:

Rrm MARR 4.000E-14 4.7088-12 4.7698-12 7.220E-16-1.000E+OO O.OOOE+OO O.OOOE+OO BONE SUR 6.020E-14 6.5148-12 6.598E-12 9.990E-16-l.OOOE+OO O.OOOE+OO 0.000E+OO THYROID 4.130E 14 4.4732-12 4.531E-12 6.860B-16-1.000E+OO O.OOOE+OO 0.000E+OO REMAINDER 3.910E-14 4.5908-12 4.650E-12 7.040E-16-l.OOOE+OO O.OOOE+OO O.OOOE+OO EFFEC'I'IVE 4.1208-14 4.7738-12 4.835E-12 7.3208-16-1.000E+OO O.OOOE+OO O.OOOE+OO SKIN (FGR) l.370E-13 8.8028-11 8.916£-11 1.350E-14-l.OOOE+OO O.OOOE+OO 0.000E+OO Kr-8H GONADS 9.9008-14 2.2788-11 2.6558-11 1.BOOE-15-1.000E+OO O.OOOE+OO O.OOOE+OO BREAST 1.llOE-13 2.177E-11 2.5378-11 l.720E-15 1.000E+OO O.OOOE+OO O.OOOE+OO LUNGS 1.0108-13 2.139E-11 2.4938-11 1.690E-15-1.000E+OO O.OOOE+OO O.OOOE+OO RED MARR l.OOOE-13 2.190E-11 2.552E-11 1.730E-15-1.000E+OO 0.000E+OO O.OOOE+OO BONE SUR 1.390E-13 2.886E-ll 3.363E-11 2.280E-15-l.OOOE+OO 0.0008+00 O.OOOE+OO THYROID l.030E-13 2.012E-ll 2.345E-11 1.590E-15-1.000E+OO O.OOOE+OO O.OOOE+OO REMAINDER 9.7908-14 2.1398-11 2.493E-11 l.690E-15-l.OOOE+OO O.OOOE+OO 0.0008+00 EFFECTIVE l.020E-13 2.202E-11 2.567E-11 1.740E-15-1.000E+OO O.OOOE+OO 0.0008+00 SKIN(FGR) l.350E-13 5.6078-11 6.534E-11 4.430E-15-1.000E+OO O.OOOE+OO O.OOOE+OO Rb-86 GONADS 4.7108-15 2.788E-12 5.187E-11 9.7408-17-1.000E+OO l.340E-09 2.lSOE-09 BREAST 5.3408-15 2.6628-12 4.9538-11 9.3008-17-1.000E+OO 1.330E-09 2.140E-09 LTMGS 4.710£-15 2.553E-12 4.750E-ll 8.920E-17-1.000E+OO 3.300E-09 2.140E 09 RED MARR 4.6408-15 2.619E-12 4.873E-ll 9.lSOE-17-1.000E+OO 2.320E-09 3.720E-09 BONE SUR 7.0508-15 3.635E-12 6.764E-ll 1.270E-16-l.OOOE+OO 4.2708-09 6.8608-09 THYROID 4.840E-15 2.599E-12 4.8368-11 9.0BOE-17-1.000E+OO 1.3308 09 2.140B-09 REMAINDER 4.5208-15 2.5428-12 4.7298-11 8.880E-17-1.000E+OO 1.3808-09 2.3308-09 EFFECTIVE 4.8108-15 2.6658-12 4.9588-11 9.310E-17-1.000E+OO 1.7908-09 2.530£-09 SKIN (FGR) 4.BSOE-14 2.210E-10 4.1118-09 7.720E-15-1.000E+OO 0.000E+OO 0.000E+OO Rb-88 GONADS 3.260E-14 O.OOOE+OO 0.0008+00 O.OOOE+00-1.000E+OO 1.310E-12 2.780E-12 BREAST 3.670E-14 O.OOOE+OO O.OOOE+OO 0.0008+00-l.OOOE+OO 1.430E-12 2.820E-12 LUNGS 3.310E-14 0.000E+OO O.OOOE+OO 0.000E+00-1.000E+OO 1.470E-10 2.910E-12 RED MARR 3.300E-14 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO l.450E-12 2.760E-12 BONE SUR 4.620E-14 0.000E+OO 0.0008+00 O.OOOE+00-1.000E+OO l.470E-12 2.750E-12 THYROID 3.370E-14 O.OOOE+OO O.OOOE+OO 0.000E+00-1.000E+OO l.370E-12 2.430E-12 REMAINDER 3.2108-14 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO 1.JBOE-11 1.SOOE-10 EFFECTIVE 3.3608-14 0.0008+00 O.OOOE+OO O.OOOE+00-1.000E+OO 2.260E-ll 4.710E-11 SK.IN (FGR) l.830E-13 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO 0.000E+OO O.OOOE+OO Sr-90 GONADS 7.780E-18 9.590E-15 2.014E-13 3.330E-19-1.000E+OO 2.690E-10 5.040E-11 BREAST 9.490E-18 l.OOBE-14 2.ll6E-13 3.SOOE-19-1.000E+OO 2.690E-10 5.0408-11 LUNGS 6.440E-18 6.307E-15 1.324E-13 2.190£-19-1.000E+OO 2.860E-06 5.040E-ll RED MARR 5.440E-18 5.558E-15 1.167E-13 1.930E-19-1.000E+OO 3.280E-08 6.450E-09 BONE SUR 2.280E-17 2.393E-14 5.0258-13 8.310E-19 l.OOOE+OO 7.090E-08 1.390E-08 THYROID 7.330E-18 7.1718-15 l.506E-13 2.490E-19-1.000E+OO 2.690E-10 5.040E-ll REMAINDER 6.llOE-18 6.422E-15 l.348E-13 2.230£-19-1.000E+OO 5.730E-09 6.700E-09 BFFECTIVE 7.530E-18 8.179E-15 1.717£-13 2.8408-19-1.000E+OO 3.510E-07 3.230E-09 SKIN (FGR) 9.200E-15 4.0328-12 8.465E-11 1.400E-16-1.0008+00 O.OOOE+OO O.OOOE+OO Sr-91 GONADS 4.819E-14 2.155E-11 5.062E-11 1.0268-15-1.000E+OO 5.669E-ll 2.520E-10 BREAST 5.477E-14 2.059E-11 4.B38E-11 9.8068-16-1.0008+00 l.775E-11 3.676E-11 LUNGS 4.8038-14 l.970E-11 4.6268-11 9.376E-16-1.000E+OO 2.170E-09 1.0SSE-11 RED MARR 4.691E-14 2.0llE-11 4.722E-11 9.570E-16-1.000E+OO 2.275E-ll 5.659E-11 BONE SUR 7.674E-14 2.852E-11 6.709E-11 l.360E-15-1.000E+OO l.306E-11 2.0708-11 THYROID 4.938E-14 2.035E-11 4.782E-11 9.6938-16-1.000E+OO 9.930E-12 l.968E-12 RE1"AINDER 4.610E-14 1.948E-11 4.573E-11 9.268E-16-1.000E+OO 5.8028-10 2.557E-09 EFFECTIVE 4.924E-14 2.057E-ll 4.8328-11 9.793E-16-l.OOOE+OO 4.547E-10 8.455E-10 SKIN (FGR) 9.93BE-14 1.74BE-10 3.9878-10 B.OBOE-15-1.000E+OO O.OOOE+OO O.OOOE+OO Sr-92 GONADS 6.610E-14 1.593E-11 l.BJOE-11 l.300E-l5-1.000E+OO l.020E-ll 8.180E-11 BREAST 7.480E-14 1.520£-11 1.745E-ll 1.240E-15-l.OOOE+OO 6.490E-12 1.700E-ll LTmGS 6.670E-l4 1.4838-11 l.703E-11 l.210E-15-l.OOOE+OO l.OSOE-09 7.2208-12 RED !4J\RR 6.620E-14 1.520E-ll l.745E-ll 1 240E-15-l.OOOE+OO 6.980E-12 2.290E-11 BONE SUR 9.490E-14 2.0lOE-11 2.308E-11 1.640E-15-l.OOOE+OO 4.360E-12 8.490E-12 THYROID 6.820E-14 1.446E-ll 1.661E-11 1.1808-15-1.000E+OO 3.920E-12 1.300E-12 REMAINDER 6.450E-14 1.4718-11 1.689E-11 1.200E-15-l.OOOE+OO 2.900E-10 1.720E-09 EFFECTIVE 6.790E-14 1.532E-11 l.759E-ll 1.250E-15-1.000E+OO 2.lBOE-10 5.430E-10 SKIN (FGRl 8.560E-14 2.280E-ll 2.618E-11 1.860E-15-1.000E+OO O.OOOE+DO O.OOOE+OO Y-90

CALCULATION NO. PM-1168 REV. No. 0 PAGE NO. 57 of: 67 GONADS l.B90E-16 l.586E-13 1.601E-12 5.7SOE-18-1.000E+OO 5.170E-13 l.430E-14 BREAST 2.200E**l6 1.578E-13 1.593E-12 5.720E-18-l.OOOE+OO 5.170E-13 l.270E-14 I,UNGS l.770E-16 l.313E-13 l.326E-12 4.760E-18-l.OOOE+OO 9.310E-09 1.260E-14 RED MARR 1..620E-16 1.261E-13 1.273E-12 4.570E-18-l.OOOE+OO l.520E-ll 3.700E-13 BONE SUR 4.440E-16 3.228E-13 3.259E-12 l.l?OE-17-1.000E+OO l.SlOE-11 3.670E-13 THYROID l.B70E-16 1.3BSE-13 l.398E-12 5.020E-18-l.OOOE+OO 5.170E-13 1.260E-14 REMAINDER l.680E-16 l.291E-13 1.303E-12 4.6BOE-18-l.OOOE+OO 3.870E-09 9.680E-09 EFFECTIVE l.900E-16 l.46BE-13 1.4B2E-12 5.320E-18-1.000E+OO 2.280E-09 2.910E-09 SKIN(FGR) 6.240E-l4 2.897E-10 2.924E-09 l.OSOE-14-1.000E+OO O.OOOE+OO O.OOOE+OO Y-91 GONADS 2.560E-16 l.756E-13 3.546E-12 6.llOE-18-1.000E+OO 8.200E-12 3.540E-12 BREAST 2.930E-16 1.713E-13 3.459E-12 S.960E-18-1.000E+OO 8.920E-12 5.540E-13 LUNGS 2.500E-16 1.526E-13 3.082E-12 5.310E-18-1.000E+OO 9.870E-08 2.020E-13 RED MARR 2.410E-16 l.521E-13 3.070E-12 5.290E-18-1.000E+OO 3.190E-10 6.590E-12 BONE SUR 4.560E-16 2.903E-13 5.862E-12 1.0lOE-17-1.000E+OO 3.180E-10 6.130E-12 THYROID 2.600E-16 l.564E-13 3.157E-12 5.440E-18-1.000E+OO 8.SOOE-12 l.290E-13 REMAINDER 2.390E-16 1.509E-13 3.047E-12 5.2SOE-18-l.OOOE+OO 4.200E-09 8.570E-09 EFFECTIVE 2.600E-16 1.650E-13 3.332E-12 5.740E-18-1.000E+OO 1.320E-08 2.570E-09 SKIN (FGR) 3.850E-14 l.989E-10 4.016E-09 6.920E-15-l.OOOE+OO O.OOOE+OO O.OOOE+OO Y-92 GONADS 1.270E-14 3.855E-12 4.872E-12 2.650E-16-1.000E+OO 2.610E-12 l.960E-11 BREAST l.440E-14 3.680E-12 4.652E-12 2.530E-16-1.000E+OO l.SOOE-12 3.550E-12 LUNGS 1.270E-14 3.535E-12 4.46BE-12 2.430E-16-1.000E+OO 1.240E-09 l.390E-12 RED MARR l.250E-14 3.608E-12 4.560E-12 2.480E-16-l.OOOE+OO 2.070E-12 4.910E-12 BONE SUR l.950E-14 5.091E-12 6.435E-12 3.500E-16-l.OOOE+OO 1.510E-12 1.750E-12 THYROID 1.300E-14 3.579E-12 4.523E-12 2.460E-16-1.000E+OO 1.050E-12 1.770E-13 REMAINDER l.220E-14 3.506E-12 4.431E-12 2.410E-16-1.000E+OO 2.030E-10 l.700E-09 EFFECTIVE l.300E-14 3.680E-12 4.652E-12 2.530E-16-1.000E+OO 2.ll.OE-10 5.150E-10 SKIN(FGR) l.140E-13 2.022E-10 2.556E-l0 1.390E-14-1.000E+OO O.OOOE+OO O.OOOE+OO Y-93 GONADS 4.670E-15 2.108E-12 4.989E-12 9.510E-17-l.OOOE+OO 5.310E-12 2.200E-11 BREAST 5.300E-15 2.026E-12 4.794E-12 9.140E-17-l.OOOE+OO l.740E-12 3.130E-12 LUNGS 4.680E-15 l.937E-12 4.585E-12 8.740E-17-l.OOOE+OO 2.520E-09 8.670E-13 RED MARR 4.5BOE-15 l.972E-12 4.669E-12 8.900E-17-l.OOOE+OO 4.040E-12 4.930E-12 BONE SUR 7.580E-15 2.948E-12 6.977E-12 1.330E-16-l.OOOE+OO 3.140E-12 1.730E-12 THYROID 4.790E-15 1.908E-12 4.516E-12 8.610E-17-l.OOOE+OO 9.260E-13 1.260E-13 REMAINDER 4.510E-15 l.919E-12 4.543E-12 8.660E-17-l.OOOE+OO 9.250E-10 4.090E-09 EFFECTIVE 4.BOOE-15 2.021E-12 4.784E-12 9.120E-17-l.OOOE+OO 5.820E-10 l.230E-09 SKIN(FGR) 8.500E-14 2.726E-10 6.452E-10 1.230E-14-l.OOOE+OO O.OOOE+OO O.OOOE+OO Zr-95 GONADS 3.530E-14 2.182E-ll 4.421E-10 7.590E-16-1.000E+OO l.880E-09 8.160E-10 BREAST 4.0lOE-14 2.084E-11 4.223E-10 7.25DE-16-1.000E+OO l.910E-09 1.0SOE-10 LUNGS 3.510E-14 1.989E-ll 4.030E-10 6.920E-16-1.000E+OO 2.170E-09 2.340E-11 RED MARR 3.430E-14 2.030E-ll 4.112E-10 7.060E-16 .. l.OOOE+OO l.300E-OB 2.140E-10 BONE SUR 5.620E-14 2.875E-11 5.824E-10 1.000E-15-1.000E+OO 1.030E-07 4.860E-10 THYROID 3.610E-14 2.076E-li 4.205E-10 7.220E-16-1.000E+OO l.440E-09 8.270E-12 REMAINDER 3.360E-14 l.963E-11 3.978E-10 6.830E-16-1.000E+OO 2.2BOE-09 2.530E-09 EFFECTIVE 3.600E-14 2.078E-11 4.211E-10 7.230E-16-1.000E+OO 6.390E-09 1.020E-09 SKIN(FGR) 4.500E-14 2.561E-11 5.190E-10 8.910E-16-1.000E+OO O.OOOE+OO O.OOOE+OO Zr-97 GONADS 4.331E-14 2.179E-11 7.799E-11 9.253E-16-l.OOOE+OO 1.840E-10 6.228E-10 BREAST 4.92BE-14 2.083E-11 7.455E-ll 8.846E-16-1.000E+OO 4.706E-11 8.137E-11 LUNGS 4.322E-14 1.992E-ll 7.127E-11 8.456E-16-l.OOOE+OO 4.108E-09 1.770E-ll RED MARR 4.224E-14 2.034E-11 7.279E-ll 8.634E-16-1.000E+OO 6.376E-11 1.302E-10 BONE SUR 6.897E-14 2.881E-11 1.031E-10 1.224E-15-1.000E+OO 3.504E-11 4.558E-11 THYROID 4.443E-14 2.061E-ll 7.377E-11 8.755E-16-1.000E+OO 2.315E-11 2.671E-12 REMAINDER 4.139E-14 1.966E-11 7.035E-ll 8.345E-16-1.000E+OO 2.041E-09 6.990E-09 EFFECTIVE 4.432E-14 2.078E-11 7.438E-11 8.824E-16-1.000E+OO l.171E-09 2.283E-09 SKIN(FGR) 9.835E-14 2.281E-10 B.148E-10 9.587E-15-l.OOOE+OO O.OOOE+OO O.OOOE+OO Nb-95 GONADS 3.660E-14 2.253E-11 4.435E-10 7.BSOE-16-1.000E+OO 4.320E-10 8.050E-10 BREAST 4.160E-14 2.150E-11 4.231E-10 7.490E-16-1.000E+OO 4.070E-10 1.070E-10 LUNGS 3.650E-14 2.055E-ll 4.045E-10 7.160E-16-1.000E+OO 8.320E-09 2.740E 11 RED MARR 3.560E-14 2.lOlE-11 4.135E-10 7.320E-16-l.OOOE+OO 4.420E-10 l.990E-10 BONE SUR 5.790E-14 2.957E-11 5.819E-10 l.030E-15-l.OOOE+OO 5.130E-10 2.940E-10 THYROID 3.750E-14 2.144E-11 4.220E-10 7.470E-16-1.000E+OO 3.580E-10 1.180E-ll REMAINDER 3.490E-14 2.032E~11 4.000E-10 7.080E-16-l.OOOE+OO 1.070E-09 1.470E-09

CALCULATION NO. PM-116!-l REV. No. 0 PAGE NO. 58 of: 67 EFFECTIVE 3.740E-14 2.147E-11 4.2268-10 7.480E-16-l.OOOE+OO l.570E-09 6.9508-10 SKIN (FGR) 4.300E-14 2.598E-11 S.112E-10 9.0SOE-16-1.000E+OO O.OOOE+OO O.OOOE+OO Mo-99 GONADS 7.lJOE-15 4.282E-12 4.4038-11 1.550E-16 1.000E+OO 9.SlOE-11 2.lBOE-10 BREAST 8.130E-15 4.116E-12 4.233E~ll 1.490E 16-1.000E+OO 2.750E-ll 3.430E-ll LUNGS 7.0GOE-15 3.8678-12 3.977E-ll 1.400E-16-1.000E+OO 4.290E-09 l.510E-11 RED MARR 6.820E-15 3.9238-12 4.034E-11 1.420E-16-1.000E+OO 5.240E-ll 8.320E-ll BONE SUR 1.240E-14 6.lOSE-12 6.278E-ll 2.2108-16-1.000E+OO 4.130E-11 6.320E-ll THYROID 7.270E-15 4.0338-12 4.147E-11 1.460E-16-l.OOOE+OO l.520E-1J 1.0308-11 REMAINDER 6.740E-15 3.812E-12 3.9208-11 1.3808-16-1,000E+OO l.740E-09 4.280E-09 EFFECTIVE 7.280E-15 4.061E-12 4.176E-11 1.470E-16-l.OOOE+OO 1.070E-09 1.360E-09 SKIN(FGR) 3.140E-14 l.039E-10 1.0688-09 3.760E-15-l.OOOE+OO 0.000E+OO 0.0008+00 Tc-99m GONADS 5.750E-15 2.334E-12 3.8778-12 1.240E-16-l.OOOE+OO 2.7708-12 9.750E-12 BREAST 6.6SOE-15 2.258E-12 3.7528-12 l.200E-16-l.OOOE+OO 2.1508-12 3.5708-12 LUNGS 5.4908-15 2.1278-12 3.5338-12 1.1308-16 1.0008+00 2.2808-11 3.140E-12 RED MARR 4.9108-15 2.070E-12 3.439E-12 1.lOOE-16-1.000E+OO 3.3608-12 6.2908-12 BONE SUR 1.6308-14 5.3838-12 8.9428-12 2.860E-16-l.OOOE+OO 2.6208-12 4.0608-12 THYROID 5.7508-15 2.145E-12 3.5648-12 1.140E-16-l.OOOE+OO 5.0lOE-11 8.460E-11 REMAINDER 5.150E-15 2.070E-12 3.4398-12 1.1008-16-1.000E+OO l.020E-ll 3.3408-11 EFFECTIVE 5.8908-15 2.277E-12 3.7838-12 1.210E-16-l.OOOE+OO 8.BOOE-12 1.6808-11 SKIN(FGR) 7.140E-15 2.710E-12 4.5028-12 1.440E-16-1.000E+OO 0.000E+OO O.OOOE+OO Ru-103 GONADS 2.191E-14 1.404E-11 2.7838-10 4.892E-16-l.OOOE+OO 3.0708-10 5.720E-10 BREAST 2.512E-14 1.3508-11 2.677E-10 4.705E-16-1.000E+OO 3.1108-10 1.2008-10 LUNGS 2.lBOE-14 l.273E-11 2.5228-10 4.4328-16-1.000E+OO l.561E-08 7.3108-11 RED MARR 2.lOOE-14 1.2878-11 2.5518-10 4.483E-16-l.OOOE+OO J.190E-10 1.660E-10 BONE SUR 3.8928-14 1.958E-ll 3.882E-10 6.82JE-16-1.000E+OO 2.370E-10 9.631E-11 THYROID 2.2418-14 l.331E-11 2.639E-10 4.638E-16-1.0008+00 2.5708-10 6.250E-11 REMAINDER 2.0808-14 1.248E-ll 2.4728-10 4.3468-16-1.000E+OO 1.2508-09 2.llOE-09 EFFECTIVE 2.251E-14 l.332E-ll 2.641E-10 4.642E-16-l.OOOE+OO 2.421E-09 8.271E-10 SKIN(FGR) 2.774E-14 1.7858-11 3.543E-10 6.229E-16-1.000E+OO O.OOOE+OO 0.0008+00 Rul05 GONADS 3.720F.-14 l.327E-11 1.861E-11 8.070E-16-1.000E+OO l.590E-11 9.670E-ll BREAST 4.240E-14 1.271E-ll l.783E-11 7.7308-16-1.000E+OO 6.610E-12 l.590E-11 LUNGS 3.700E-14 1.210E-11 1.697E-ll 7.360E-16-1.000E+OO 5.730E-10 6.210E-12 RED MARR 3.590E-14 1.230E-11 l.725E-11 7.480E-16-1.000E+OO 7.700E-12 2.3508-11 BONE SUR 6.280E-14 1.809E-ll 2.537E-11 1.lOOE-15-1.000E+OO 4.620E-12 8.890E-12 THYROID 3.BOOE-14 1.260E-11 1.766E-11 7.660E-16-1.000E+OO 4.150E-12 1.820E-12 REMAINDER 3.540E-14 l.189E-11 1.667E-11 7.230E-16-1.000E+OO l.610E-10 8.540E-10 EFFECTIVE 3.BlOE-14 l.265E-11 1.773E-ll 7.690E-16-1.000E+OO l.230E-10 2.870E-10 SKIN(FGR) 6.730E-14 7.368E-11 l.033E-10 4.480E-15-1.000E+OO O.OOOE+OO O.OOOE+OO Ru-106 GONADS 1.0lOE-14 6.411E-12 1.340E-10 2.230E-16-l.OOOE+OO 1.JOOE-09 1.640E-09 BREAST l.160E-14 6.152E-12 1.286E-10 2.140E-16-1.000E+OO l.780E-09 1.4408-09 LUNGS 1.0lOE-14 5.836E-12 1.220E-10 2.030E-16-1.000E+OO 1.040E-06 1.4208-09 RED MARR 9.750E-15 5.893E-12 1.232E-10 2.0SOE-16-1.000E+OO l.760E-09 1.460E-09 BONE SUR 1.720E-14 8.883E-12 1.856E-10 3.090E-16-1.000E+OO 1.6108-09 l.430E-09 THYROID l.030E-14 6.066E-12 l.268E-10 2.llOE-16-1.000E+OO 1.7208-09 1.410E-09 REMAINDER 9.630E-15 5.721E-12 1.196E-10 1.990E-16 l.OOOE+OO l.200E 08 2.llOE-08 EFFECTIVE 1.040E-14 6.095E-12 1.274E-10 2.120E-16-l.OOOE+OO l.290E-07 7.400E-09 SKIN(FGR) 1.0908-13 4.0B2E-10 8.531E-09 1.420E-14-1.000E+OO O.OOOE+OO O.OOOE+OO Rh-105 GONADS 3.640E-15 2.127E-12 l.411E-11 7.980E-17-1.000E+OO 2.llOE-11 5.BOOE-11 BREAST 4.160E-15 2.063E-12 1.369E-11 7.740E-17-l.OOOE+OO 5.610E-12 B.970E-12 LUNGS 3.570E-15 l.935E-12 l.284E-ll 7.260E-17-1.000E+OO 9.580E-10 3.860E-12 RED MARR 3.380E-15 l.946E-12 1.291E-11 7.300E-17-1.000E+OO 7.770E-12 l.470E-11 BONE SUR 7.530E-15 3.332E-12 2.210E-11 1.250E-16-1.000E+OO 4.4608-12 6.750E-12 THYROID 3.680E-15 1.983E-12 1.3168-11 7.440E-17-l.OOOE+OO 2.880E-12 2.910E-12 REiifiAINDER 3.390E-15 1.885E-12 1.250E-11 7.070E-17-l.OOOE+OO 4.530E-10 l.270E-09 EFFECTIVE 3.720E-15 2.0JlE-12 1.347E-11 7.620E-17-l.OOOE+OO 2.SBOE-10 3.990E-10 SKIN(FGR) 1.070E-14 4.691E-12 3.112E-11 1.760E-16-1.000E+OO 0.0008+00 O.OOOE+OO Sb-127 GONADS 3.260E-14 l.985E-ll 2.441E-10 7.lOOE-16-1.000E+OO 2.520E-10 6.140E-10 BREAST 3.720E-14 1.904E-ll 2.341E-10 6.BlOE-16-1.000E+OO 9.120E-ll 7.600E-11 LUNGS 3.240E-14 1.809E-11 2.224E-10 6.470E-16-1.000E+OO 6.940E-09 1.570E-ll RED MARR 3.140E-14 l.834E-11 2.255E-10 6.560E-16-l.0008+00 1.610E-10 1.330E-10

CALCULATION NO. PM-J Ui8 NO. 59 of 67 BONE SUR 5.520E-14 2.720E-11 3.345E-10 9.730E-16-1.000E+OO l.340E-10 5.240E-11 THYROID 3.330E-14 1 .884E-11 2.317E-10 6.740E 16-1.000E+OO 6.lSOE-11 4.640E-12 REMAINDER 3.090E-14 1.775E-11 2.lBJE-10 6.JSOE-16-1.000E+OO 2.330E-09 S.870E-09 EPPECTlVE 3.3308-14 1.8908-11 2.3248-10 6.760E-16-1.000E+OO 1.6308-09 1.950E-09 SKIN(FGR) 5.SBOE-14 7.967E-ll 9.799E-10 2.BSOE-15-1.000E+OO O.OOOE+OO O.OOOE+OO m)-U9 GONAD,S 6.970E*l4 2.336£-11 1.231E 11 1.440E-15-1.000E+OO 2.1508-11 l.SlOE-10 BREAST 7.9108-14 2.2228-11 3.074E-11 l.370E-15-l.0008+00 1.280E-11 2.5608-11 LUNGS 6.9801':-14 2.141E*l1 2.962E-ll l.320E-15-l.OOOE+OO 8.980E*10 9.390E-12 RED MARH 6.tl60E-l4 2.190E-ll 3.029E-11 1.350E-15 l.OOOE+OO 1.700E-11 3.670E-11 BONE SUR l.070E-13 3.033E-ll 4.196E-11 1.870E-15-1.000E+OO 1.460E-ll l.340E-11 THYROID 7.160E-14 2.174E-ll 3.007E-11 1.340E 15 l.OOOE+OO 9.720E-12 1.470E-12 REMAINDER 6.710E-14 2.l25E**ll 2.9398-11 l.310E-l5-l.OOOE+OO l.870E-10 l.450E-09 EFFECTIVE 7.140E-14 2.238E-11 3.096E-ll 1.380E-15-l.OOOE+OO 1.740E-10 4.840E-l0 SKIN(FGR) l .OSOE-13 8.273E-ll 1.l44E-10 5.lOOE-15-1.000E+OO O.OOOE+OO 0.000E+OO Te*-12'/

GONADS 2.370E-16 l.l91E-13 2.661E-13 5.480E-18-1.000E+OO 2.020E-12 4.020E-12 BREAST 2.730E-16 1.158E 13 2.5BBE-13 5.330E-18-l.OOOE+OO l.880E-12 3.000E-12 LUNGS 2.320E-16 l.060E-13 2.370E-13 4.880E-18 1.000E+OO 4.2708-10 2.890E-12 RED MARR 2.210E-16 l.058E-13 2.365E-13 4.870E-18-1.000E+OO 4.090E-12 6.570E-l2 BONE SUR 4.6508-16 1.862E-13 4.162E-13 8.570E-18-1.0008+00 4.090E-12 6.4608-12 THYROID 2.4008-16 l.106E-13 2.472E-13 5.090E-18-1.000E+OO 1.8408-12 2.8608-12 REMAINDER 2.210E-16 1.036E-13 2.316E-13 4.770E-18-l.OOOE+OO 1.llOE-10 6 130E-10 EFFECTIVE 2.420E-l6 1.125E-13 2.515E-13 5.180E-18-l.OOOE+OO 8.600E-11 l.870E-10 SKIN(FGR) 1.140E-14 l.173E-ll 2.622E-11 5.400E-16-1.000E+OO O.OOOE+OO O.OOOE+OO Te-1;nm GONADS l.900E-16 4.689E-13 9.642E-12 1.630E-17 1.000E+OO l.lOOE-10 l.250E-10 BREAST 2.690E-l6 5.150E-13 l.059E-11 l.790E-17-1.000E+OO 1.lOOE-10 9.740E-ll LUNGS 7.6208-17 l.602E-13 3.295E-12 5.570E-18-1.000E+OO 3.340E-08 9.620E-11 RED MARR 6.430E-17 1.249E-13 2.567E-12 4.340E-1B-1.000E+OO 5.360E-09 5.430E-09 BONE SUR 3.940E-16 9.00SE-13 l.852E-ll 3.130E 17-1.000E+OO 2.040E-08 2.070E-08 THYROID l.500E-16 2.779E-13 5.714E-12 9.660E-18-1.000E+OO 9.660E-11 9.4308-11 REMAINDER B.640E-17 1.999E-13 4.lllE-12 6.950E*l8-l.OOOE+OO 1.6608-09 2.980E-09 EFFECTIVE l.470E-16 3.2518-13 6.684E-12 l.130E-17-l.OOOE+OO 5.810E-09 2.2308-09 SKIN (FGR) 8.490E-16 l.496E-12 3.076E-ll 5.200E 17 l.OOOE+OO O.OOOE+OO O.OOOE+OO Te-*129 GONADS 2.710E 15 3 B89E-13 3.9228-13 6.5108-17-1.000E+OO 5.0SOE-13 1.590E-12 BREAST 3.120E-l5 3.BOOE-13 3.8328-13 6.360E-17-1.000E+OO 5.390E-13 6.0SOE-13 LUNGS 2.640E-15 3.2988-13 3.326E-13 5.520E 17 1.000E+OO 1.5308-10 4.910E-13 RED MARR 2.S40E-15 3.29BE-13 3.326E-13 S.520E-17-1.000E+OO 6.190E-13 7.640E-13 BONE SUR 4.BBOE-15 5.753E-13 5.802E-13 9.630E-17-l.OOOE+OO 6.220E-13 5.400E-13 THYROID 2.740E-15 3.5258-13 3.555E-13 5.900E-17-l.OOOE+OO 5.090E-l3 3.360E-13 REMAINDER 2.520E-15 3.2628-13 3.289E-13 5.4608-17-1.000E+DO 7.280E-12 l.790E-l0 EFFECTIVE 2.750E-15 3.590E-13 3.621E-13 6.0108-17-1.000E+OO 2.090E-ll 5.450E-ll SKIN (FGR) 3.570E-14 3.429E-ll 3.458E-11 5.740E-15-l.OOOE+OO O.OOOE+OO O.OOOE+OO Te-129m GONADS 3.321E-15 2.206E-l2 4.799E-ll 8.561E-17-l.OOOE+OO l.783E-10 2.420E-10 BREAST 3.B38E-15 2.lBlE-12 4.739E-ll 8.454E-17-1.000E+OO l.694E-10 1.6648-10 I.UN GS 3.176E-15 1.741E-12 3.815E-ll 6.BOBE-17-1.000E+OO 4.040E-08 l.593E-10 RED MAR.R 3.071E-15 l.729E-12 3.793E-ll 6.768E-17-l.OOOE+OO 3.lOOE-09 3.SOOE-09 BONE SUR 5.772E-15 3.287E-12 7.147E-11 l.275E-16-l.OOOE+OO 7.050E-09 7.9908-09 THYROID 3.341E-15 l.923E-12 4.201E-11 7.495E-17-1.000E+OO l.563E-10 l.572E-10 REMAINDER 3.0488-15 l.746E-12 3.822E-ll 6.819E-17-l.OOOE+OO 3.275E-09 7.196E-09 EFFECTIVE 3.337E-15 l.974E-12 4.308E-ll 7.686E-17-1.000E+OO 6.484E-09 2.925E-09 SKIN(FGR) 3.BllE-14 l.SOlE-10 3.360E-09 6.00lE-15-l.OOOE+OO O.OOOE+OO O.OOOE+OO Te-131m GONADS 7.292E-14 4.020E-ll 2.343E-10 l.535E-15-1.000E+OO 2.345E--10 7.415E-10 BREAST 8.286E-14 3.853E-11 2.246E-10 1.472E-15-l.OOOE+OO 9.309E-11 1.361.E-10 LUNGS 7.265E-14 3.657E-l1 2.l31E-10 1.397E-15-1.000E+OO 2.296E-09 6.335E-11 RED MARR 7.0978-14 3.736E-ll 2.178E-l0 1.427E*l5-l.OOOE+OO l.417E-10 2.435E-10 BONE SUR 1.174E-13 5.467E-ll 3.189E-10 2.090E-15-1.0008+00 2.276E*-10 3.248£-10 THYROID 7.471E-14 3.741E-ll 2.181E-10 l.429E-15-l.OOOE+OO 3.669E-08 4.383E-08 REMAINDER 6.965E-14 3.626E-ll 2.1138-10 l.385E-15-l.OOOE+OO 9.509E>lO 3.1538-09 EFFECTIVE 7.463E-14 3.8258-11 2.2298-10 1.461E-15-l.OOOE+OO l.75BE-09 2.514E-09 SKIN(F'GR) l.038E-l3 l.033E-10 6.188E-10 4.056E-15-l.OOOE+OO O.OOOE+OO O.OOCE+OO Te-132 GONADS l.020E-14 6.812E-12 7.706E-ll 2.450E-16-1.000E+OO 4.lSOE-10 S.410E-10

CALCULATION NO. REV. No. 0 PAGE NO. 60 of BREAST l.lBOE-14 6.756E-12 7.643E-ll 2.430E-16-l.OOOE+OO 3.630E-10 3.SOOE-10 LUNGS 9.650E-15 5.727E-12 6.479E-11 2.0GOE-16-1.000E+OO 1.670E 09 3.300E-10 RF;D MARR 8.9SOE-15 5.SBBE-12 6.J22E-11 2.0lOE-16-1.000E+OO 4.270E-10 4.440E-10 BONE SUR 2.420E-14 1.273E-11 l.441E-10 4.580E-16-l.OOOE+OO 7.120E-10 8.JOOE-10 THYROID l.020E-14 5.978E-12 6.762E-11 2.150E-l6-1.000E+OO 6.280E-08 5.950E-08 REMAJNDER 9.160E 15 5.644E-12 6.385E-11 2.0JOE-16-1.000E+OO 7.890E-10 l .490E-09 EFFEC'I'IVE l.030E-14 6.339E-12 7.171E-ll 2.2BOE-16-1.000E+OO 2.SSOE-09 2.540E-09 SKIN (FGR) l.390E-14 8.313E-12 9.405E-ll 2.990E-16-1.000E+OO O.OOOE+OO O.OOOE+OO 1**131 GONADS l.780E-14 1.119E-11 l.789E-10 3.940E-16-l.000EP00 2.530E-11 4.070E-ll BREAST 2.040E-14 l.OB2E-11 l.730E-10 3.BlOE-16-1.000E+OO 7.BBOE-11 l.210E-10 LUNGS l.760E-14 1.016E-ll l.626E-10 3.580E-16 l.OOOE+OO 6.570E-10 1.020E-10 RED MARR 1.680E-14 l.022E-11 1.635E-10 3.600E-16 1.000E+OO 6.260E-11 9.440E-11 BONE SUR 3.450E-14 1.675E-11 2.679E-10 5.900E-16-1.000E+OO 5.730E-11 8.720E-11 THYROID l.BlOE-14 l.053E-11 1.685E-10 3.710E-16-l .OOOE+OO 2.920E*07 4.760E-07 REMAINDER l.670E-14 9.908E-12 1.585E-10 3.490E-16-l.OOOE+OO 8.030E-11 l.570E-10 EFFECTIVE 1.820E-14 l.067E-ll l.707E-10 3.760E-16-l.OOOE+OO 8.890E-09 l.440E-08 SKIN (FGR) 2.980E 14 1.8258-11 2.920E-10 6.430E-16-1.0008+00 O.OOOE+OO 0.000E+OO I-132 GONADS l.090E-13 2.5238-11 2.771E-11 2.320E-15-1.000E+OO 9.950E-12 2.330E-ll BREAST 1.2408-13 2.414E-ll 2.652E-11 2.220E-15-1.000E+OO l.410E-ll 2.520E-11 LUNGS 1.090E-13 2.305E-ll 2.532E-11 2.120E-15-l.OOOE+OO 2.710E-10 2.6408-11 RED MARR 1.070E-13 2.360E-ll 2.592E-11 2.170E-15-l.OOOE+OO 1.4008-11 2.460E-11 BONE SUR l.730E-13 3.3278-11 3.6558-11 3.0GOE-15-1.000E+OO 1.240E-ll 2.190E-ll THYROID 1.120E-13 2.381E-11 2.616E-ll 2.190E-15-1.000E+OO l.740E-09 3.870E-09 REMAINDER l.050E-13 2.283E-11 2.509E-11 2.lOOE-15-1.000E+OO 3.780E-11 1.650E-10 EFFECTIVE 1.120E-13 2.403E-11 2.640E-11 2.210E-15-1.000E+OO l.OJOE-10 1.8208-10 SKIN (FGR) 1.580E-13 8.1998-11 9.0078-11 7.540E 15-1.000E+OO O.OOOE+OO O.OOOE+OO I-L33 GONADS 2.870E-14 1.5858-11 6.7488-11 6.270E-16-l.0008+00 1.950E-ll 3.630E-ll BREAST 3.280E-14 1.519E-11 6.468E-11 6.0lOE-16-1.000E+OO 2.940E-11 4.680E-ll LUNGS 2.860E-14 1.446E-11 6.156E-11 5.720E-16-1.000E+OO 8.200E-10 4.530E 11 RED MARR 2.770E-14 l.466E-ll 6.242E-ll 5.BOOE-16-1.000E+OO 2.720E-11 4.300E-11 BONE SUR 4.870E-14 2.161E-ll 9.202E-11 8.550E-16-1.0008+00 2.520E-ll 4.070E-11 THYROID 2.930E-14 1.502E-11 6.393E-ll 5.940E-16-1.000E+OO 4.BGOE-08 9.1008-08 REMAINDER 2.730E-14 1.418E-11 6.038E-ll 5.610E-16-l.0008+00 5.000E-11 1.550E-10 EFFECTIVE 2.940E-14 l.509E-ll 6.425E-11 5.970E-16-l.OOOE+OO l.580E-09 2.BOOE-09 SKIN (FGR) 5.830E-14 1.150E-10 4.897E-10 4.550E-15-l.OOOE+OO O.OOOE+OO 0.000E+OO I-134 GONADS 1.270E-13 1.200E-11 l.202E-11 2.640E-15-1.0008+00 4.250E-12 1.lOOE-11 BREAST l.440E-13 1.145E-11 l.147E-11 2.520E-I5-l.OOOE+OO 6.170E-12 1.170E-11 LUNGS l.270E-13 1.lOOE-11 1.102E-11 2.4208-15-1.000E+OO 1.430E-10 1.260E-ll RED MARR l.250E-13 l.127E-11 1.1298-11 2.480E-15-l.OOOE+OO 6.0BOE-12 1.090E-ll BONE SUR l.960E-13 1.568E-ll 1.571E-ll 3.450E-15-l.0008+00 5.310E-12 9.320E-12 THYROID l.300E-13 1.127E-11 1.129E-11 2.480E-15-l.OOOE+OO 2.BBOE-10 6.210E-10 REMAINDER 1.220E-13 1.091E-ll 1.0938-11 2.400E-15-1.000E+OO 2.270E-11 l.340E-10 EFFECTIVE l.300E-13 1.150E-ll 1.152E-11 2.530E-15-l.OOOE+OO 3.550E-11 6.660E-11 SKIN(FGR) 1.870E-13 4.477E-11 4.485E-11 9.850E-15 1.000E+OO O.OOOE+OO 0.0008+00 I-135 GONADS B.078E-14 3.113E-ll 5.489E-11 1.599E-15-1.000E+OO l.700E-11 3.610E-11 BREAST 9.143E-14 2.971E-11 5.240E-11 l.526E-15-l.OOOE+OO 2.3408-11 3.BSOE-11 LUNGS 8.145E-14 2.886E-ll 5.089E-11 l.482E-15-1.000E+OO 4.410E-10 3.750E-ll RED MARR B.054E-14 2.965E-11 5.2288-11 l.523E-15-1.000E+OO 2.240E-ll 3.650£-11 BONE SUR l.184E-13 3.983E-ll 7.024E-ll 2.046E-15-1.000E+OO 2.0lOE-11 3.3608-11 THYROID B.324E-14 2.852E-11 5.030E-ll l.465E-15-1.000E+OO 8.460E-09 l.790E-08 REJ\'IAINDER 7.B61E-14 2.B83E-11 5.084E-11 1.481E-15-l.OOOE+OO 4.700E-ll 1.540E-10 EFFECTIVE 8.294E-14 2.989E-11 5.271E-11 1.535E-15-1.000E+OO 3.320E-10 6.0BOE-10 SKIN (FGR) 1.1568-13 9.826E-11 1.733E-10 5.047E-15-l.OOOE+OO 0.0008+00 O.OOOE+OO Xe-131m GONADS 4.570E-16 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO BREAST 6.020E-16 O.OOOE+OO 0.000E+OO O.OOOE+00-1.000E+OO O.OOOE+OO 0 OOOE+OO LUNGS 2.670E-16 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO 0.000E+OO O.OOOE+OO RED YiARR 2.270E-16 O.OOOE+OO O.OOOE+OO O.OOOE+00--1.000E+OO O.OOOE+OO O.OOOE+OO BONE SUR 1.060E-15 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO THYROID 3.910E-16 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO REMAINDER 2.710E-16 O.OOOE+OO O.OOOE+OO O.ODOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO EFFECTIVE 3.890E-16 O.OOOE+OO 0.000E+OO O.OOOE+00-1.000E+OO O.OOOE+OO 0.000E+OO

CALCULATION NO. PM-1168 REV. No. O PAGE NO. 61 of, 67 SKIN (FGR) 4.820E-15 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO Xe-133 GONADS 1.610E-15 l.465E-12 2.052E-11 5.200E-17-l.OOOE+OO O.OOOE+OO O.OOOE+OO BREAST l.960E-15 l.505E-12 2.107E-11 5.340E-17-1.000E+OO O.OOOE+OO O.OOOE+OO LUNGS 1.320E-15 l.045E-12 1.464E-11 3.710E-17-1.000E+OO O.OOOE+OO O.OOOE+OO RED MARR l.O?OE-15 8.791E-13 1.231E-ll 3.120E-17-l.OOOE+OO O.OOOE+OO O.OOOE+OO BONE SUR 5.130E-15 4.254E-12 5.958E-ll 1.SlOE-16-1.000E+OO O.OOOE+OO O.OOOE+OO THYROID 1.510E-15 1.181E-12 1.653E-11 4.190E-17-1.000E+OO O.OOOE+OO O.OOOE+OO REMAINDER l.240E-15 1.042E-12 l.460E-11 3.700E-17-1.000E+OO O.OOOE+OO O.OOOE+OO EFFECTIVE 1.560E-15 l.299E-12 l.819E-ll 4.610E-17-1.000E+OO O.OOOE+OO O.OOOE+OO SKIN(FGR) 4.970E-15 l.953E-12 2.734E-11 6.930E-17-1.000E+OO O.OOOE+OO O.OOOE+OO Xe-133m GONADS 1.420E-15 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO BREAST 1.700E-15 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO LUNGS 1.190E-15 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO RED MARR l.lOOE-15 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO BONE SUR 3.230E-15 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO THYROID l.360E-15 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO REMAINDER l.lSOE-15 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO EFFECTIVE l.370E-15 O.OOOE+OO O.OOOE+OO O.OOOE+00-1..000E+OO O.OOOE+OO O.OOOE+OO SKIN(FGR) 1.040E-14 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO xe-135 GONADS 1.170E-14 S.4SSE-12 1.194E-11 2.530E-16-1.000E+OO O.OOOE+OO O.OOOE+OO BREAST 1.330E-14 5.325E-12 1.166E-ll 2.470E-16-l.OOOE+OO O.OOOE+OO O.OOOE+OO LUNGS l.130E-14 4.959E-12 1.086E-11 2.300E-16-l.OOOE+OO O.OOOE+OO O.OOOE+OO RED MARR 1.0?0E-14 4.959E-12 1.086E-ll 2.300E-16-l.OOOE+OO O.OOOE+OO O.OOOE+OO BONE SUR 2.570E-14 9.120E-12 l.997E-ll 4.230E-16-1.000E+OO O.ODOE+OO O.OOOE+OO THYROID l.180E-14 5.023E-12 l.lOOE-11 2.330E-16-1.000E+OO O.OOOE+OO O.OOOE+OO REMAINDER 1.080E-14 4.829E-12 l.058E-ll 2.240E-16-l.OOOE+OO O.OOOE+OO O.OOOE+OO EFFECTIVE l.190E-14 5.217E-12 l.142E-ll 2.420E-16-l.OOOE+OO O.OOOE+OO O.OOOE+OO SKIN(FGR) 3.120E-14 4.506E-11 9.867E-ll 2.090E-15-l.OOOE+OO O.OOOE+OO O.OOOE+OO Xe-135m GONADS 2.000E-14 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO BREAST 2.290E-14 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO LUNGS l.9BOE-14 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO RED MARR 1.910E-14 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO BONE SUR 3.SOOE-14 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO

'rHYROID 2.040E-14 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO REMAINDER l.890E-14 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO EFFECTIVE 2.040E-14 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO SKIN (FGR) 2.970E-14 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO Xe-138 GONADS 5.590E-14 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO BREAST 6.320E-14 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO

.LUNGS 5.660E-14 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO RED MARR 5.600E-l4 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO BONE SUR 8.460E-14 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO THYROID 5.770E-14 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO REMAINDER 5.490E-14 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO EFFECTIVE 5.770E-14 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO SKIN(FGR) 1..0?0E-13 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO O.OOOE+OO O.OOOE+OO Cs-134 GONADS 7.400E-14 4.607E-ll 9.646E-10 1.600E-15-l.OOOE+OO l.300E-08 2.060E-08 BREAST 8.430E-14 4.406E-1.l 9.224E-10 l.530E-15-l.OOOE+OO 1.0BOE-08 l.720E-08 LUNGS 7.370E-14 4.204E-11 8.802E-10 l.460E-15-l.OOOE+OO 1.180E-08 l.760E-08 RED MARR 7.190E-14 4.262E-11 8.922E-10 l.480E-15-l.OOOE+OO l.180E-08 l.870E-08 BONE SUR l.200E-13 6.lOSE-11 l.278E-09 2.120E-15-l.OOOE+OO l.lOOE-08 l.740E-08 THYROID 7.570E-14 4.377E-11 9.163E-10 l.520E-15-l.OOOE+OO l.llOE-08 l.760E-08 REMAINDER 7.060E-14 4.147E-ll 8.681E-10 1.440E-15-l.OOOE+OO 1.390E-08 2.210E-08 EFFECTIVE 7.570E-14 4.377E-11 9.163E-10 l.520E-15-l.OOOE+OO 1.250E-08 1.980E-OB SKIN(FGR) 9.450E-14 6.249E-ll l.308E-09 2.l?OE-15-1.000E+OO O.OOOE+OO O.OOOE+OO Cs-136 GONADS 1.040E-13 6.223E-ll l.102E-09 2.180E-15-l.OOOE+OO l.880E-09 3.040E-09 BREAST l.180E-13 5.966E-ll l.056E-09 2.090E-15-l.OOOE+OO 1,670~-09 2.650E-09 LUNGS l.040E-13 S.710E-11 l.OllE-09 2.000E-15-1.000E+OO 2.320E-09 2.620E-09 RED MARR 1.0lOE-13 5.824E-ll l.031E-09 2.040E-15-1.000E+OO 1.860E-09 2.950E-09 BONE SUR l.660E-13 8.422E-ll l.491E-09 2.950E-15-l.OOOE+OO l.?OOE-09 2.710E-09

CALCULATION NO. PM-1168 REV. No. 0 PAGE NO. 62 of 67 THYROID 1.070E-13 5.852E-11 1.036E-09 2.0SOE-15-1.000E+OO 1.730E-09 2.740E-09 REMAINDER 9.9SOE-14 5.652E-11 1.00lE-09 1.980E-15-1.000E+OO 2.190E-09 3.520E-09 EFFECTIVE 1.0608-13 5.966E-11 l.056E-09 2.090E-15-l.OOOE+OO 1.980E-09 3.040E-09 SKIN(FGR) 1.250E-13 7.251E-ll 1.284E-09 2.540E-15-1.000E+OO O.OOOE+OO O.OOOE+OO Cs-137 GONADS 2.669E-14 1.669E-11 3.530E-10 5.840E-16-1.000E+OO 8.760E-09 l.390E-08 BREAST 3.047E-14 l.596E-11 3.376E-10 5.585E-16-1.000E+OO 7.840E-09 1.240E-08 LUNGS 2.649E-14 1.517E-11 3.209E-10 5.309E-16-1.000E+OO 8.820E-09 1.270E-08 RED MARR 2.583E-14 1.542E-11 3.260E-10 5.394E-16-l.OOOE+OO 8.300E-09 l.320E-08 BONE SUR 4.382E-14 2.238E-11 4.734E-10 7.832E-16-1.000E+OO 7.940E-09 1.260E-08 THYROID 2.725E-14 1.588E-11 3.358E-10 5.556E-16-1.000E+OO 7.930E-09 1.260E-08 REMAINDER 2.536E-14 1*.490E-11 3.152E-10 5.215E-16-l.OOOE+OO 9.120E-09 l.450E-08 EFFECTIVE 2.725E-14 l.585E-11 3.353E-10 5.546E-16-l.OOOE+OO 8.630E-09 l.350E-08 SKIN(FGR) 4.392E-14 5.253E-11 l.llOE-09 l.836E-15-l.OOOE+OO O.OOOE+OO O.OOOE+OO Cs-138 GONADS 1.170E-13 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO 3.280E-12 8.000E-12 BREAST l.330E-13 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO 4.020E-12 8.000E-12 LUNGS 1.190E-13 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO l.590E-10 8.530E-12 RED MARR l.lBOE-13 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO 3.950E-12 7.370E-12 BONE SUR l.700E-13 O.OOOE+OO O.OOOE+OO 0.000E+00-1.000E+OO 3.SSOE-12 6.470E-12 THYROID 1.210E-13 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO 3.570E-12 5.730E-12 REMAINDER 1.lSOE-13 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO 2.060E-11 l.570E-10 EFFECTIVE l.210E-13 O.OOOE+OO O.OOOE+OO O.OOOE+00-1.000E+OO 2.740E-ll 5.250E-11 SKIN(FGR) 2.170E-13 O.OOOE+OO 0.000E+OO O.OOOE+00-1.000E+OO O.OOOE+OO 0.000E+OO Ba-140 GONADS 8.410E-15 5.451E-12 9.607E-11 1.910E-16-l.OOOE+OO 4.300E-10 9.960E-10 BREAST 9.640E-15 S.280E-12 9.305E-ll l.BSOE-16-1.000E+OO 2.870E-10 1.590E-10 LUNGS 8.270E-15 4.852E-12 8.SSOE-11 l.700E-16-1.000E+OO 1.660E-09 6.630E-11 RED MARR 7.930E-15 4.BSOE-12 8.601E-ll 1.710E-l6-l.OOOE+OO 1.290E-09 4.390E-10 BONE SUR l.550E-14 8.020E-12 l.413E-10 2.810E-16-1.000E+OO 2.410E-09 5.530E-10 THYROID B.530E-15 S.109E-12 9.003E-11 l.790E-16-l.OOOE+OO 2.560E-10 5.250E-ll REMAINDER 7.890E-15 4.766E-12 8.399E-11 l.670E-16-l.OOOE+OO l.410E-09 7.370E-09 EFFECTIVE 8.580E-15 5.137E-12 9.053E-ll l.800E-16-l.OOOE+OO 1.0lOE-09 2.560E-09 SKIN (FGR) 2.520E-14 5.565E-ll 9.SOBE-10 l.950E-15-1.000E+OO O.OOOE+OO O.OOOE+OO La-140 GONADS l.140E-13 6.027E-11 4.425E-10 2.240E-15-1.000E+OO 4.540E-10 l.340E-09 BREAST l.290E-13 S.758E-11 4.22BE-10 2.140E-15-l.OOOE+OO l.4SOE-10 1.BOOE-10 LUNGS 1.lSOE-13 5.596E-11 4.109E-10 2.0BOE-15-1.000E+OO 4.210E-09 4.0lOE-11 RED MARR l.140E-13 5.731E-ll 4.208E-10 2.130E-15-1.000E+OO 2.140E-10 2.SlOE-10 BONE SUR l.690E-13 7.776E-ll 5.709E-10 2.890E-15-l.OOOE+OO l.410E-10 9.770E-11 THYROID 1.lBOE-13 5.462E-11 4.0lOE-10 2.030E-15-1.000E+OO 6.870E-ll 6.400E-12 REMAINDER l.llOE-13 5.569E-11 4.089E-10 2.070E-15-l.OOOE+OO 2.120E-09 6.260E-09 EFFECTIVE l.170E-13 5.Bl2E-ll 4.267E-10 2.160E-15-1.000E+OO 1.310E-09 2.280E-09 SKIN (FGR) l.660E-13 2.217E-10 l.62BE-09 8.240E-15-1.000E+OO O.OOOE+OO O.OOOE+OO La-141 GONADS 2.330E-15 7.3l5E-13 9.675E-13 4.740E-17-l.OOOE+OO l.OlOE-11 3.770E-12 BREAST 2.640E-15 7.007E-13 9.267E-13 4.540E-17-l.OOOE+OO 9.840E-12 7.070E-13 LUNGS 2.340E-15 6.713E-13 8.B79E-13 4.350E-17-l.OOOE+OO 6.460E-10 2.720E-13 RED MARR 2.310E-15 6.852E-13 9.063E-13 4.440E-1.7-l.OOOE+OO 2.930E-11 1.070E-12 BONE SUR 3.490E-15 9.923E-13 l.312E-1.2 6.430E-17-l.OOOE+OO 1.200E-10 6.060E-13 THYROID 2.390E-15 6.590E-13 8.716E-13 4.270E-17-l.OOOE+OO 9.400E-12 5.290E-14 REMAINDER 2.260E-15 6.682E-13 8.B3BE-13 4.330E-17-1.000E+OO 2.280E-10 l.240E-09 EFFECTIVE 2.390E-15 7.007E-13 9.267E-13 4.540E-17-l.OOOE+OO l.570E-10 3.740E-10 SKIN(FGR) 6.580E-14 1.667E-10 2.204E-10 l.OBOE-14-1.000E+OO O.OOOE+OO O.OOOE+OO La-142 GONADS 1.400E-13 1.97.BE-11 2.034E-ll 2.540E-15-l.OOOE+OO 1.660E-11 6.990E-11 BREAST l.570E-13 l.885E-11 l.93BE-11 2.420E-15-l.OOOE+OO l.130E-11 1.540E-11 LUNGS l.420E-13 1.846E-ll 1.898E-11 2.370E-15-1.000E+OO 3.0lOE-10 B.400E-12 RED MARR l.420E-13 l.900E-ll l.954E-ll 2.440E-15-l.OOOE+OO l.360E-11 l.930E-11 BONE SUR l.950E-13 2.484E-11 2.554E-ll 3.190E-15-l.OOOE+OO 1.llOE-11 7.400E-12 THYROID 1.450E-13 l.768E-11 l.B18E-11 2.270E-15-l.OOOE+OO 8.740E-12 1.160E-12 REMAINDER l.380E-13 1.B53E-11 1.906E-ll 2.380E-15-l.OOOE+OO 8.070E-11 5.200E-10 EFFECTIVE l.440E-13 1.916E-11 1.970E-11 2.460E-15-1.000E+OO 6.840E-11 l.790E-10 SKIN(FGR) 2.160E-13 9.lllE-11 9.368E-11 l.170E-14-1.000E+OO O.OOOE+OO O.OOOE+OO Ce-141 GONADS 3.380E-15 2.213E-12 4.332E-11 7.710E-17-l.OOOE+OO 5.540E-11 l.OBOE-10 BREAST 3.930E-15 2.170E-12 4.247E-11 7.560E-17-l.OOOE+OO 4.460E-11 l.llOE-11

CALCULATION NO. PM*HM~ REV. No. 0 PAGE NO, 63 ofr LUNGS 3.170E-15 l.951E-12 3.B20E-11 6.BOOE-17 l.DOOE+OO 1.670E-08 1.430E-12 RED MARR 2.830E-15 1.860E-12 3.641E-11 6.480E-17-1.000E+OO 8.960E-11 3.390E-11 BONE SUR 9.410E-15 5.166E-12 l.OllE-10 l.BDOE-16-1.000E+OO 2.540E 10 2.300E-ll THYROID 3.350E-15 2.003E-12 3.922E-11 6.980E-17-1.000E+OO 2.550E-11 1.BOOE-13 REMAINDER 2.9BOE 15 1.894E-12 3.708E-11 6.6008-17 1.000E+OO 1.2GOE-09 2.500E-09 EFFECTIVE J.430E-15 2.llBE-12 4.146E-11 7.JBOE-17*1.000E+OO 2.420E-09 7.830E-10 SKIN(FGR) 1.020E-14 J.78BE-12 7.416E-ll 1.320E-l6-l.OOOE+OO O.OOOE+OO O.OOOE+OO Ce-* 143 GONADS l.280E-14 7.900£-12 4.958E-ll 2.980E-16-l.OOOE+OO 7.530E-ll 2.120E-10 BREAST 1.4708-14 7.688E-12 4.825E-11 2.900E-16-1.000E+OO 1.660E-11 2.320E-ll LUNGS l.230E-14 6.893E-12 4.325E-11 2.600E-16-l.OOOE+OO J.BBOE-09 3.B20E-12 RED MARR 1.170E-14 6.787E-12 4.259E-11 2.SGOE-16-1 .OOOE+OO 2.9608-11 5.0708-11 BONE SUR 2.520E-14 1.323E-11 8.302E-ll 4.990E-16-1.000E+OO l.640E-11 1.610E-11 THYROID 1.280E-14 7.211E-12 4.525E-ll 2.720E-16-1.000E+OO 6.2JOE-12 4.350E-13 REMAINDER l.170E-14 6.734E-12 4.226E-11 2.540E-16-l.OOOE+OO l.420E-09 J.890E-09 EFFECTIVE l.290E-14 7.J96E-12 4.6428-11 2.790E-16-1.000E+OO 9.160E-10 1.230E-09 SKIN(FGR) 3.960E-14 l.OSBE-10 6.6388-10 J.990E-15-1.000E+OO O.OOOE+OO O.OOOE+OO Ce-144 GONADS 2.725E-15 6.328E-13 l.319E-11 6.0BBE-17-1.000E+OO 2.390E-10 6.987E-ll BREAST 3.129E-15 6.274E-13 l.307E-11 5.922E-17-l.OOOE+OO 3.480E-10 1.223E-11 LUNGS 2.639E-15 5.228E-13 l.089E-ll 5.362E-17-l.OOOE+OO 7.911E-07 6.551E-12 RED MARR 2.507E-15 4.755E-13 9.9078-12 5.247E-17 l.OOOE+OO 2.BBOE-09 8.923E-ll BONE SUR 5.441E-15 1.646E-12 3.429E-11 1.127E-16-1.000E+OO 4.720E-09 1.280E-10 THYROID 2.753E-15 5.529E-13 l.152E-ll 5.418E-17-1.000E+OO 2.920E-10 5.154E-12 REMAINDER 2.534E-15 5.086E-13 1.0GOE-11 5.283E-17-l.0008+00 1.910E-08 l.890E-OB EFFECTIVE 2.773E-15 5.909E-13 1.2318-11 5.766E-17-l.OOOE+OO l.OlOE-07 5.711E-09 SKIN(FGR) 8.574E-14 7.64BE-13 1.5948-11 l.250E-14-l.OOOE+OO O.OOOE+OO O.OOOE+OO Pr-143 GONADS 2.130E-17 2.264E-14 4.032E-13 7.9JOE-19-1.000E+OO 4.370E-lB 8.990E-18 BREAST 2.SSOE-17 2.330E-14 4.149E-13 8.160E-19-l.OOOE+OO 2.220E-18 1.090E-18 LUNGS 1 860E-17 1.642E-14 2.923E-13 5.750E-19-1.000E+OO l.330E-08 1.910£ . 19 RED MARR 1. 6 2 0 E- 17 l . 4 9 3 E- 14 2 . 6 5 9 E - 13 5 . 2 3 0 E 1. 0 0 0 E + 0 0 1 . 4 8 0 E- 11 l. 0 3 0 E-12 BONE SUR 5.930E**l7 5.454E-14 9.7llE-13 1.910E-18-1.000E+OO l.490E-11 l.030E-12 THYROID 2.050E-17 l.802E-14 3.2088-13 6.310E-19-l.OOOE+OO 1.680E-18 2.660E-20 REMAINDER l.760E-17 J..6*12E-14 2.923E-13 5.750E-19-1.000E+OO l.970E-09 4.220E-09 EFFECTIVE 2.lOOE-17 2.002E-14 J.564E-*13 7.0lOE-19-1.000E+OO 2.190E-09 l.270E-09 SKIN(F'GR) l.760E-14 5.711E-11 l.017E-09 2.000E-15-1.000E+OO O.OOOE+OO O.OOOE+OO Nd-147 GONADS 6.UOE-*15 4.218E-12 7.235E-1l l.4BOE-16-l.OOOE+OO 8.410E-11 l.790E-10 BREAST 7.120E-15 4.132E-12 7.0BBE-11 1.4SOE-16-1.000E+OO 3.4508-11 1.870E-11 LUNGS 5.820E-15 3.648E-12 6.257E-11 l.280E-16-l.OOOE+OO l.060E-08 2.4408-12 RED MARR 5.400E-15 3.505E-12 6.013E-11 l.230E-16-l.OOOE+OO 9.190E-11 5.050E*ll BONE SUR 1. 320E-14 8. 265E--12 l. 418E-10 2. 900E l. OOOE+OO 3. 260E-10 2. 2208-11 THYROID 6.120E-15 J.876E-12 6.648E-11 1.360E-16-l.OOOE+OO 1.820E-ll 2.640E-13 REMAINDER 5.530E-15 3.562E-126.lllE11 1.250E--16-*l.OOOE+OO l.760E-09 3.760E-09 EFFECTIVE 6.190E-15 3.961E-12 6.795E-11 l.390E-16-l.OOOE+OO l.850E-09 l.lBOE-09 SKIN(FGR) 1.950E-14 3.135E-11 5.377E-10 l.lOOE-15-l.OOOE+OO 0.000E+OO O.OOOE+OO Np-239 GONADS 7.530E-15 4.691E-12 4.3808-11 l.710E-16-1.000E+OO 7.450E-11 1.620E-10 BREAST 8.730E-15 4.636E-12 4.329E-ll l.690E-16-1.000E+OO 1.630E-11 1.720E-11 LUNGS 7.lBOE-15 4.115E-12 3.842E-11 1.SOOE-16-1.000E+OO 2.360E-09 2.400E-12 RED MARR 6.SOOE-15 4.00SE-12 3.740E-ll l.460E-16-l.OOOE+OO 2.0BOE-10 4.660E-11 BONE SUR 2.000E-14 l.OOlE-11 9.349E-11 3.650E-16-1.000E+OO 2.0JOE-09 J.590E-11 THYROID 7.520E-15 4.197E-12 3.919E-11 l.SJOE-16-1.000E+OO 7.620E-12 2.070E-13 REMAINDER 6.760E-15 4.00SE-12 3.740E-11 l.4GOE-16-l.OOOE+OO 9.590E-10 2.7708-09 EFFECTIVE 7.690E-15 4.471E-12 4.175E-11 l.630E-16-l.OOOE+OO 6.?BOE-10 8.820E-10 SKIN(FGR) 1.6008-14 7.215E-12 6.737E-ll 2.6JOE-16-l.OOOE+OO 0.000E+OO O.OOOE+OO Pu-241 GONADS 7.190E-20 6 653E-17 l.396E-15 2.310E-21-l.OOOE+OO 2.760E-07 5.6GOE-11 BREAST B.670E-20 7.229E-17 1.517E-15 2.510E-2l-1.000E+OO 2.J.40E-11 2.790E-15 LUNGS 6.480E-20 4.090E-17 8.584E-16 1.420E-21-l.OOOE+OO 3.lBOE-06 4.480E-15 RED MARR 5.630E-20 4.003E-17 8.403E-16 1.390E-21-l.OOOE+OO l.430E-06 2.780E-10 BONE SUR 2.190E-19 1.385E-16 2.908E-15 4.BlOE-21-1.000E+OO 1.780E-05 J.480E-09 THYROID 6.980E-20 4.522E-17 9.491E-16 1.570E-21-1.000E+OO 9.lSOE-12 l.OlOE-15 REMAINDER 6.090E-20 4.291E-17 9.007E-16 1.490E-21-1.000E+OO 6.020E-07 1.8508-10 EFFECTIVE 7.250E-20 5.558E-17 l.167E-15 1.930E-21-l.OOOE+OO l.340E-06 2.070E-10 SKIN(FGR) 1.l?OE-19 2.033E-16 4.268E-15 7.060E-21-l.OOOE+OO O.OOOE+OO O.OOOE+OO

Ctn-242 GONADS 7.830E-18 4.893E**14 l.OlJE-12 1.700E-18-1.000E+OO 5.700E-07 5.200E*09 BREAST l.480E*l7 G .159E-14 1.275El2 2.140E-18-1.000E+OO 9.440E-JO 8.950E-l2 LUNGS J.UOE-18 3.022E-15 6.257E-14 l.050E-19-l.OOOE+OO 1. 550.E-05 8.840E-12 RED MARR 1.890E-l8 6.:)621'>15 1.3S9E-13 2.280E-19-1.000E+OO 3.900E-06 3.570li>-08 BONE SUR l.060E-J.7 4.231E-14 8.759E-*13 1.470E-18-1.000E+OO 4.870E-05 4.460E-07 THYROID 4.9l0E-18 1. 261E** 14 2.61.0E-13 4.JBOE 19-1.000E+OO 9.41.0E--10 8.820E**l2 REMAINDER 2.270E-lB 1.079.E-14 2.235E-13 3.750E-l9-1.000E+OO 2.450E-06 4.020E-08 EFFF:CTIVE 5.690£ 18 2.751E-14 5.697E-13 9.560E-19-l.OOOE+OO 4.670E-06 3.lOOE-08 SKIN (FGR) 4.290E-17 2.?00E-13 5.'i89E-l2 9.380E-18-l.OOOE+OO O.OOOE+OO O.OOOE+OO

[ CALCULATION NO. PM-H68 *-------------*-r*

REV. No. 0 PAGE NO. 65 of 1st Pass Attributes - General Overview Yes No Attribute The purpose/scope is clear and well defined. You should be able to

[8J D understand the purpose without resorting to consultation with the preparer.

(4.3.2)

IZ1 D The reason or need for the product is clearly discussed. (4.3.2)

You possess the proper knowledge and skill sets needed for the review. If

[ZJ D additional expertise is needed, those reviews have been scheduled to ensure that appropriate knowledgeable "experts" are utilized for reviews.

The Methodology is appropriate for the purpose and scope of the document, IZ1 D and is clearly documented.

CALCULATION NO. PM-1168 REV. No. 0 PAGE NO. 66 of 67 2nd Pass Attributes - Technical Review Yes No Attribute IZI D Input Parameters are clearly listed, defined with source documentation.

IZI D The Inputs are valid and are referenced to a quality documented reference.

IZI D Assumptions are reasonable and well documented.

The Methodology is appropriate and Equations Used have been verified-IZI D Ensure proper methodology & units If an Alternate Calculation Tools or Methods was used as the review method, IZI D that analysis has been attached to the final document The Numerical calculations and computations have been verified correct-IZI D validate the numbers The acceptance criteria is consistent with the Design Basis, Design Standards IZI D and applicable codes.

Does the analysis consider new potential failure modes and disposition them as IZI D appropriate? If none are indicated, is this appropriate?

Does the product consider the most limiting or bounding design basis IZI D conditions?

Are the results consistent with actual plant response and do they appear IZI D reasonable?

IZI D Does the conclusion clearly support the purpose as described?

CALCULATION NO. PM..1168 REV.No. 0 PAGE NO. 67 of 67 3rd Pass Attributes .-Adminlstratvt Yes No .. Attribute

~ D Check references--are they the correct rev 181 0 Check procedures used- are they the correct rev

~ 0 Assumptions are reasonable anct weU documented

~ 0 Check for Spelling Errors, Punctuation and Grammar

~ 0 Check for simplicity and readability 181 D Are the proper forms included in the document and filled out correctly

~ D Check Page and Attachment Numbering

~ D Right Boxes Checked on Fonns l?5l D Proper process has been used, Major Rev, Minor Rev, EC/ECR etc.

l2SI D Appropriate boxes are signed off or marked NIA

' I ..